US20120003313A1 - Dpp iv inhibitor formulations - Google Patents

Dpp iv inhibitor formulations Download PDF

Info

Publication number
US20120003313A1
US20120003313A1 US13/230,133 US201113230133A US2012003313A1 US 20120003313 A1 US20120003313 A1 US 20120003313A1 US 201113230133 A US201113230133 A US 201113230133A US 2012003313 A1 US2012003313 A1 US 2012003313A1
Authority
US
United States
Prior art keywords
pharmaceutical composition
tablet
diluent
film
disintegrant
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US13/230,133
Inventor
Anja Kohlrausch
Patrick Romer
Gerd Seiffert
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Boehringer Ingelheim International GmbH
Original Assignee
Boehringer Ingelheim International GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36972901&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=US20120003313(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Boehringer Ingelheim International GmbH filed Critical Boehringer Ingelheim International GmbH
Priority to US13/230,133 priority Critical patent/US20120003313A1/en
Publication of US20120003313A1 publication Critical patent/US20120003313A1/en
Priority to US13/467,505 priority patent/US20120219622A1/en
Priority to US13/735,078 priority patent/US20130122089A1/en
Priority to US14/877,019 priority patent/US20160022687A1/en
Priority to US15/655,269 priority patent/US20170312287A1/en
Priority to US16/357,357 priority patent/US11033552B2/en
Priority to US17/319,325 priority patent/US12178819B2/en
Priority to US18/944,220 priority patent/US20250064818A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2813—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/2853—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers, poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2893—Tablet coating processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4891—Coated capsules; Multilayered drug free capsule shells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets

Definitions

  • the present invention relates to pharmaceutical compositions of selected DPP IV inhibitors, their preparation and their use to treat selected medical conditions.
  • DPP-IV dipeptidyl peptidase IV
  • CD26 The enzyme DPP-IV (dipeptidyl peptidase IV) also known as CD26 is a serine protease known to lead to the cleavage of a dipeptide from the N-terminal end of a number of proteins having at their N-terminal end a prolin or alanin residue. Due to this property DPP-IV inhibitors interfere with the plasma level of bioactive peptides including the peptide GLP-1 and are considered to be promising drugs for the treatment of diabetes mellitus.
  • DPP-IV inhibitors with a primary or secondary amino group show incompatibilities, degradation problems, or extraction problems with a number of customary excipients such as microcrystalline cellulose, sodium starch glycolate, croscarmellose sodium, tartaric acid, citric acid, glucose, fructose, saccharose, lactose, maltodextrines.
  • customary excipients such as microcrystalline cellulose, sodium starch glycolate, croscarmellose sodium, tartaric acid, citric acid, glucose, fructose, saccharose, lactose, maltodextrines.
  • the compounds themselves are very stable, they react with many excipients used in solid dosage forms and with impurities of excipients, especially in tight contact provided in tablets and at high excipient/drug ratios.
  • a pharmaceutical composition according to the present invention is intended for the treatment of to achieve glycemic control in a type 1 or type 2 diabetes mellitus patient and comprises a DPP-IV inhibitor with an amino group, especially a free or primary amino group, as an active ingredient, a first and second diluent, a binder, a disintegrant and a lubricant.
  • An additional disintegrant and an additional glidant are a further option.
  • the compositions can be used to treat rheumatoid arthritis, obesity and osteoporosis as well as to support allograft transplantation.
  • Diluents suitable for a pharmaceutical composition according to the invention are cellulose powder, dibasic calciumphosphate anhydrous, dibasic calciumphosphate dihydrate, erythritol, low substituted hydroxypropyl cellulose, mannitol, pregelatinized starch or xylitol. Among those diluents mannitol and pregelatinized starch are preferred.
  • Diluents preferred as the second diluent are the above mentioned diluents pre-gelatinized starch and low-substituted hydroxypropylcellulose (L-HPC) which show additional binder properties.
  • Lubricants suitable for a pharmaceutical composition according to the invention are talc, polyethyleneglycol, calcium behenate, calcium stearate, hydrogenated castor oil or magnesium stearate.
  • the preferred lubricant is magnesium stearate.
  • Binders suitable for a pharmaceutical composition according to the invention are copovidone (copolymerisates of vinylpyrrolidon with other vinylderivates), hydroxypropyl methylcellulose (HPMC), hydroxypropylcellulose (HPC), polyvinylpyrrolidon (povidone), pregelatinized starch, low-substituted hydroxypropylcellulose (L-HPC), copovidone and pregelatinized starch being preferred.
  • binders pregelatinized starch and L-HPC show additional diluent and disintegrant properties and can also be used as the second diluent or the disintegrant.
  • Disintegrants suitable for a pharmaceutical composition according to the present invention are corn starch, crospovidone, low-substituted hydroxypropylcellulose (L-HPC) or pregelatinized starch, corn starch being preferred.
  • colloidal silicon dioxide can be used as an optional glidant colloidal silicon dioxide.
  • An exemplary composition according to the present invention comprises the diluent mannitol, pregelatinized starch as a diluent with additional binder properties, the binder copovidone, the disintegrant corn starch, and magnesium stearate as the lubricant.
  • Dosage forms prepared with a pharmaceutical compositions according to the present invention contain active ingredients in dosage ranges of 0.1-100 mg. Preferred dosages are 0.5 mg, 1 mg, 2.5 mg, 5 mg and 10 mg.
  • Typical pharmaceutical compositions comprise (% by weight)
  • active ingredient 40-88% diluent 1, 3-40% diluent 2, 1-5% binder, 5-15% disintegrant, and 0.1-4% lubricant.
  • Preferred pharmaceutical compositions comprise (% by weight)
  • compositions according to the invention are intended for oral use and can be used in the dosage form of a capsule, a tablet or a film-coated tablet.
  • the film coat represents 2-4%, preferably 3% of the composition and comprises a film-forming agent, a plasticizer, a glidant and optionally one or more pigments.
  • An exemplary coat composition may comprise hydroxypropylmethyl-cellulose (HPMC), polyethylene glycol (PEG), talc, titanium dioxide and optionally iron oxide.
  • DPP-IV inhibitors with a primary amino group and salts thereof such as any DPP-IV inhibitor and salt thereof defined by formula (I)
  • R1 is ([1,5]naphthyridin-2-yl)methyl, (quinazolin-2-yl)methyl], (quinoxalin-6-yl)methyl, (4-Methyl-quinazolin-2-yl)methyl, 2-Cyano-benzyl, (3-Cyano-quinolin-2-yl)methyl, (3-Cyano-pyridin-2-yl)methyl, (4-Methyl-pyrimidin-2-yl)methyl, or (4,6-Dimethyl-pyrimidin-2-yl)methyl, and R2 is 3-(R)-amino-piperidin-1-yl, (2-amino-2-methyl-propyl)-methylamino or (2-(S)-amino-propyl)-methylamino.
  • Preferred DPP IV inhibitor compounds are the following compounds and salts thereof:
  • compositions according to the invention can be prepared by a wet granulation process.
  • Alternative methods for granulation of active ingredient and excipients with a granulation liquid are fluid bed granulation or one-pot granulation.
  • the granulation liquid is a solvent such as water, ethanol, methanol, isopropanol, acetone, preferably purified water, and contains a binder such as copovidone.
  • the solvent is a volatile component, which does not remain in the final product.
  • the active ingredient and the other excipients with exception of the lubricant are premixed and granulated with the aqueous granulation liquid using a high shear granulator.
  • the wet granulation step is followed by an optional wet sieving step, drying and dry sieving of the granules. For example a fluid bed dryer can then be used for drying.
  • the dried granules are sieved through an appropriate sieve.
  • a suitable conventional blender such as a free fall blender followed by addition of the lubricant such as magnesium stearate and final blending in the blender.
  • an exemplary wet granulation process for the preparation of a pharmaceutical composition according to the present invention comprises
  • part of the exipients such as part of a disintegrant (e.g. corn starch) or a diluent (e.g. pregelatinized starch) or an additional disintegrant (crospovidone) can be added extragranular prior to final blending of step g.
  • a disintegrant e.g. corn starch
  • a diluent e.g. pregelatinized starch
  • an additional disintegrant crospovidone
  • the granulate produced in steps a to e is produced in a one pot high shear granulation process and subsequent drying in a one pot granulator.
  • the final blend is further filled into capsules.
  • the final blend is further compressed into tablets of the target tablet core weight with appropriate size and crushing strength, using an appropriate tablet press.
  • a coating suspension is prepared and the compressed tablet cores are coated with the coating suspension to a weight gain of about 2-4%, preferably about 3%, using a standard film coater.
  • the film-coating solvent is a volatile component, which does not remain in the final product.
  • An active DPP IV inhibitor ingredient with a primary amino group and all other excipients with exception of magnesium stearate are blended in a high shear blender. This pre-mix is sieved through a 1 mm sieve. After addition of magnesium stearate the pre-mix is blended in a free fall blender to produce the final blend. The final blend is compressed into tablets using a suitable tablet press.
  • the following compositions can be obtained:
  • Component mg/tablet %/tablet mg/tablet %/tablet Active ingredient 1.000 2.000 2.500 2.000 Mannitol 43.250 86.500 108.125 86.500 Pregelatinized starch 5.000 10.000 12.500 10.000 Magnesium stearate 0.750 1.500 1.875 1.500 Total 50.000 100.000 125.000 100.000
  • Component mg/tablet %/tablet mg/tablet %/tablet Active ingredient 5.000 2.000 10.000 2.000 Mannitol 216.250 86.500 432.500 86.500
  • An active DPP IV inhibitor ingredient with a primary amino group and all other excipients with exception of magnesium stearate are blended in a high shear blender. This pre-mix is sieved through a 1 mm sieve. After addition of magnesium stearate the pre-mix is blended in a free fall blender to produce the final blend. The final blend is compressed into tablets using a suitable tablet press.
  • the following compositions can be obtained:
  • Component mg/tablet %/tablet mg/tablet %/tablet Active ingredient 10.000 1.667 10.000 2.222 Dibasic 464.000 77.333 344.000 76.788 calciumphosphate, anhydrous Low-substituted 120.000 20.000 90.000 20.000 hydroxypropylcellulose Magnesium stearate 6.000 1.000 6.000 1.000 Total 600.000 100.000 450.000 100.000
  • Copovidone is dissolved in purified water at ambient temperature to produce a granulation liquid.
  • An active DPP IV inhibitor ingredient with a primary amino group, mannitol and part of the pregelatinized starch are blended in a suitable mixer, to produce a pre-mix.
  • the pre-mix is moistened with the granulation liquid and subsequently granulated.
  • the moist granulate is optionally sieved through a sieve with a mesh size of 1.6-3.0 mm.
  • the granulate is dried at 55° C. in a suitable dryer to a residual moisture content corresponding to 2-5% loss on drying.
  • the dried granulate is sieved through a sieve with a mesh size of 1.0 mm.
  • the granulate is blended with part of the pregelatinized starch in a suitable mixer.
  • Magnesium stearate is added to this blend after passing through a 1.0 mm sieve for delumping.
  • the final blend is produced by final blending in a suitable mixer and compressed into tablets.
  • the following tablet composition can be obtained:
  • Copovidone is dissolved in purified water at ambient temperature to produce a granulation liquid.
  • An active DPP IV inhibitor ingredient with a primary amino group, mannitol, pregelatinized starch and corn starch are blended in a suitable mixer to produce the pre-mix.
  • the pre-mix is moistened with the granulation liquid and subsequently granulated using a high shear mixer.
  • the moist granulate is optionally sieved through a sieve with a mesh size of 1.6-3.0 mm.
  • the granulate is dried at about 60° C. in a fluid bed dryer until a loss on the drying value of 2-4% is obtained.
  • the Final Blend is compressed into tablet cores.
  • Hydroxypropyl methylcellulose, polyethylene glycol, talc, titanium dioxide and iron oxide are suspended in purified water in a suitable mixer at ambient temperature to produce a coating suspension.
  • the tablet cores are coated with the coating suspension to a weight gain of about 3% to produce film-coated tablets.
  • the following tablet compositions can be obtained:
  • Copovidone is dissolved in purified water at ambient temperature to produce a granulation liquid.
  • An active DPP IV inhibitor ingredient with a primary amino group, mannitol and pregelatinized starch are blended in a suitable mixer to produce a pre-mix.
  • the pre-mix is moistened with the granulation liquid and subsequently granulated.
  • the moist granulate is optionally sieved through a suitable sieve.
  • the granulate is dried at about 50° C. in a suitable dryer until a loss on drying value of 3-5% is obtained.
  • the dried granulate is sieved through a sieve with a mesh size of 1.0 mm.
  • Magnesium stearate is passed through a 1.0 mm sieve and added to the granulate. Subsequently the final blend is produced by final blending in a suitable blender and the final blend is compressed into tablets.
  • the following tablet compositions can be obtained:
  • Copovidone is dissolved in purified water at ambient temperature to produce a granulation liquid.
  • An active DPP IV inhibitor ingredient with a primary amino group and a part of mannitol, pregelatinized starch and corn starch are blended in a suitable mixer, to produce a pre-mix.
  • the pre-mix is moistened with the granulation liquid and subsequently granulated.
  • the moist granulate is sieved through a suitable sieve.
  • the granulate is dried at about 60° C. inlet air temperature in a fluid bed dryer until a loss on drying value of 1-4% is obtained.
  • the dried granulate is sieved through a sieve with a mesh size of 1.0 mm.
  • Magnesium stearate is passed through a sieve for delumping and added to the granulate. Additionally the remaining part of the exipients are added extragranular at this process step. Subsequently the final blend is produced by final blending in a suitable blender and compressed into tablet cores.
  • Hydroxypropyl methylcellulose, polyethylene glycol, talc, titanium dioxide and iron oxide are suspended in purified water in a suitable mixer at ambient temperature to produce a coating suspension.
  • the tablet cores are coated with the coating suspension to a weight gain of about 3% to produce film-coated tablets.
  • the following formulation variants can be obtained:
  • Formulation E Component mg/Tablet %/Tablet mg/Tablet %/Tablet Active ingredient 1.000 1.111 1.000 1.111 Mannitol 23.300 25.889 66.950 74.389 Pregelatinized starch 4.500 5.000 4.500 5.000 Corn starch 4.500 5.000 4.500 5.000 Copovidone 1.350 1.500 2.700 3.000 Total (granulate) 34.650 38.500 79.650 88.500 Corn starch 4.500 5.000 4.500 5.000 4.500 5.000 Mannitol 45.000 50.000 Magnesium stearate 1.350 1.500 1.350 1.500 Total (tablet core) 90.000 100.000 90.000 100.000 100.000

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Inorganic Chemistry (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Child & Adolescent Psychology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)

Abstract

The present invention relates to pharmaceutical compositions of DPP IV inhibitors with an amino group, their preparation and their use to treat diabetes mellitus.

Description

  • This application is a continuation of U.S. application Ser. No. 11/744,701, filed May 4, 2007, which claims priority of EP 06 009 201, filed Mary 4, 2006, each of which is hereby incorporated by reference in its entirety.
    • 1. FIELD OF THE INVENTION
  • The present invention relates to pharmaceutical compositions of selected DPP IV inhibitors, their preparation and their use to treat selected medical conditions.
    • 2. DESCRIPTION OF THE PRIOR ART
  • The enzyme DPP-IV (dipeptidyl peptidase IV) also known as CD26 is a serine protease known to lead to the cleavage of a dipeptide from the N-terminal end of a number of proteins having at their N-terminal end a prolin or alanin residue. Due to this property DPP-IV inhibitors interfere with the plasma level of bioactive peptides including the peptide GLP-1 and are considered to be promising drugs for the treatment of diabetes mellitus.
    • DETAILED DESCRIPTION OF THE INVENTION
  • In attempts to prepare pharmaceutical compositions of selected DPP-IV inhibitors it has been observed, that the DPP-IV inhibitors with a primary or secondary amino group show incompatibilities, degradation problems, or extraction problems with a number of customary excipients such as microcrystalline cellulose, sodium starch glycolate, croscarmellose sodium, tartaric acid, citric acid, glucose, fructose, saccharose, lactose, maltodextrines. Though the compounds themselves are very stable, they react with many excipients used in solid dosage forms and with impurities of excipients, especially in tight contact provided in tablets and at high excipient/drug ratios. The amino group appears to react with reducing sugars and with other reactive carbonyl groups and with carboxylic acid functional groups formed for example at the surface of microcrystalline cellulose by oxidation. These unforeseen difficulties are primarily observed in low dosage ranges which are required due to the surprising potency of the selected inhibitors. Thus, pharmaceutical compositions are required so solve these technical problems associated with the unexpected potency of selected DPP-IV inhibitor compounds.
  • A pharmaceutical composition according to the present invention is intended for the treatment of to achieve glycemic control in a type 1 or type 2 diabetes mellitus patient and comprises a DPP-IV inhibitor with an amino group, especially a free or primary amino group, as an active ingredient, a first and second diluent, a binder, a disintegrant and a lubricant. An additional disintegrant and an additional glidant are a further option. Additionally the compositions can be used to treat rheumatoid arthritis, obesity and osteoporosis as well as to support allograft transplantation.
  • Diluents suitable for a pharmaceutical composition according to the invention are cellulose powder, dibasic calciumphosphate anhydrous, dibasic calciumphosphate dihydrate, erythritol, low substituted hydroxypropyl cellulose, mannitol, pregelatinized starch or xylitol. Among those diluents mannitol and pregelatinized starch are preferred.
  • Diluents preferred as the second diluent are the above mentioned diluents pre-gelatinized starch and low-substituted hydroxypropylcellulose (L-HPC) which show additional binder properties.
  • Lubricants suitable for a pharmaceutical composition according to the invention are talc, polyethyleneglycol, calcium behenate, calcium stearate, hydrogenated castor oil or magnesium stearate. The preferred lubricant is magnesium stearate.
  • Binders suitable for a pharmaceutical composition according to the invention are copovidone (copolymerisates of vinylpyrrolidon with other vinylderivates), hydroxypropyl methylcellulose (HPMC), hydroxypropylcellulose (HPC), polyvinylpyrrolidon (povidone), pregelatinized starch, low-substituted hydroxypropylcellulose (L-HPC), copovidone and pregelatinized starch being preferred.
  • The above mentioned binders pregelatinized starch and L-HPC show additional diluent and disintegrant properties and can also be used as the second diluent or the disintegrant.
  • Disintegrants suitable for a pharmaceutical composition according to the present invention are corn starch, crospovidone, low-substituted hydroxypropylcellulose (L-HPC) or pregelatinized starch, corn starch being preferred.
  • As an optional glidant colloidal silicon dioxide can be used.
  • An exemplary composition according to the present invention comprises the diluent mannitol, pregelatinized starch as a diluent with additional binder properties, the binder copovidone, the disintegrant corn starch, and magnesium stearate as the lubricant.
  • Dosage forms prepared with a pharmaceutical compositions according to the present invention contain active ingredients in dosage ranges of 0.1-100 mg. Preferred dosages are 0.5 mg, 1 mg, 2.5 mg, 5 mg and 10 mg.
  • Typical pharmaceutical compositions comprise (% by weight)
  •
    0.5-20%  active ingredient
    40-88%  diluent 1,
    3-40% diluent 2,
     1-5% binder,
    5-15% disintegrant, and
    0.1-4%  lubricant.
  • Preferred pharmaceutical compositions comprise (% by weight)
  •
    0.5-7% active ingredient
    50-75%  diluent 1,
     5-15% diluent 2,
     2-4% binder,
     8-12% disintegrant, and
    0.5-2% lubricant
  • The pharmaceutical compositions according to the invention are intended for oral use and can be used in the dosage form of a capsule, a tablet or a film-coated tablet. Typically the film coat represents 2-4%, preferably 3% of the composition and comprises a film-forming agent, a plasticizer, a glidant and optionally one or more pigments. An exemplary coat composition may comprise hydroxypropylmethyl-cellulose (HPMC), polyethylene glycol (PEG), talc, titanium dioxide and optionally iron oxide.
  • Preferred active ingredients in the context of the present invention are DPP-IV inhibitors with a primary amino group and salts thereof such as any DPP-IV inhibitor and salt thereof defined by formula (I)
  • Figure US20120003313A1-20120105-C00001
  • or formula (II)
  • Figure US20120003313A1-20120105-C00002
  • wherein R1 is ([1,5]naphthyridin-2-yl)methyl, (quinazolin-2-yl)methyl], (quinoxalin-6-yl)methyl, (4-Methyl-quinazolin-2-yl)methyl, 2-Cyano-benzyl, (3-Cyano-quinolin-2-yl)methyl, (3-Cyano-pyridin-2-yl)methyl, (4-Methyl-pyrimidin-2-yl)methyl, or (4,6-Dimethyl-pyrimidin-2-yl)methyl, and R2 is 3-(R)-amino-piperidin-1-yl, (2-amino-2-methyl-propyl)-methylamino or (2-(S)-amino-propyl)-methylamino.
  • Preferred DPP IV inhibitor compounds are the following compounds and salts thereof:
    • 1-[(4-methyl-quinazolin-2-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-(3-(R)-amino-piperidin-1-yl)-xanthine (compare WO 2004/018468, example 2(142):
  • Figure US20120003313A1-20120105-C00003
      • 1-[([1,5]naphthyridin-2-ylmethyl]-3-methyl-7-(2-butyn-1-yl)-8-((R)-3-amino-piperidin-1-yl)-xanthine (compare WO 2004/018468, example 2(252)):
  • Figure US20120003313A1-20120105-C00004
      • 1-[(Quinazolin-2-ylmethyl]-3-methyl-7-(2-butyn-1-yl)-8-((R)-3-amino-piperidin-1-yl)-xanthine (compare WO 2004/018468, example 2(80)):
  • Figure US20120003313A1-20120105-C00005
      • 2-((R)-3-Amino-piperidin-1-yl)-3-(but-2-yinyl)-5-(4-methyl-quinazolin-2-ylmethyl)-3,5-dihydro-imidazo[4,5-d]pyridazin-4-one (compare WO 2004/050658, example 136):
  • Figure US20120003313A1-20120105-C00006
      • 1-[(4-Methyl-quinazolin-2-yl)methyl]-3-methyl-7-(2-butyln-1-yl)-8-[(2-amino-2-methyl-propyl)-methylamino]-xanthine (compare WO 2006/029769, example 2(1)):
  • Figure US20120003313A1-20120105-C00007
      • 1-[(3-Cyano-quinolin-2-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-((R)-3-amino-piperidin-1-yl)-xanthine (compare WO 2005/085246, example 1(30)):
  • Figure US20120003313A1-20120105-C00008
      • 1-(2-Cyano-benzyl)-3-methyl-7-(2-butyn-1-yl)-8-((R)-3-amino-piperidin-1-yl)-xanthine (compare WO 2005/085246, example 1(39)):
  • Figure US20120003313A1-20120105-C00009
      • 1-[(4-Methyl-quinazolin-2-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-[(S)-(2-amino-propyl)-methylamino]-xanthine (compare WO 2006/029769, example 2(4)):
  • Figure US20120003313A1-20120105-C00010
      • 1-[(3-Cyano-pyridin-2-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-((R)-3-amino-piperidin-1-yl)-xanthine (compare WO 2005/085246, example 1(52)):
  • Figure US20120003313A1-20120105-C00011
      • 1-[(4-Methyl-pyrimidin-2-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-((R)-3-amino-piperidin-1-yl)-xanthine (compare WO 2005/085246, example 1(81)):
  • Figure US20120003313A1-20120105-C00012
      • 1-[(4,6-Dimethyl-pyrimidin-2-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-((R)-3-amino-piperidin-1-yl)-xanthine (compare WO 2005/085246, example 1(82)):
  • Figure US20120003313A1-20120105-C00013
      • 1-[(Quinoxalin-6-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-((R)-3-amino-piperidin-1-yl)-xanthine (compare WO 2005/085246, example 1(83)):
  • Figure US20120003313A1-20120105-C00014
  • To prepare compositions according to the invention a granulate can be prepared by a wet granulation process. Alternative methods for granulation of active ingredient and excipients with a granulation liquid are fluid bed granulation or one-pot granulation.
  • In the wet granulation process the granulation liquid is a solvent such as water, ethanol, methanol, isopropanol, acetone, preferably purified water, and contains a binder such as copovidone. The solvent is a volatile component, which does not remain in the final product. The active ingredient and the other excipients with exception of the lubricant are premixed and granulated with the aqueous granulation liquid using a high shear granulator. The wet granulation step is followed by an optional wet sieving step, drying and dry sieving of the granules. For example a fluid bed dryer can then be used for drying.
  • The dried granules are sieved through an appropriate sieve. After addition of the other excipients with exception of the lubricant the mixture is blended in a suitable conventional blender such as a free fall blender followed by addition of the lubricant such as magnesium stearate and final blending in the blender.
  • Thus an exemplary wet granulation process for the preparation of a pharmaceutical composition according to the present invention comprises
    • a. dissolving a binder such as copovidone in a solvent such as purified water at ambient temperature to produce a granulation liquid;
    • b. blending a DPP-IV inhibitor, a diluent, and a disintegrant in a suitable mixer, to produce a pre-mix;
    • c. moistening the pre-mix with the granulation liquid and subsequently granulating the moistened pre-mix for example in a high shear mixer;
    • d. optionally sieving the granulated pre-mix through a sieve with a mesh size of at least 1.0 mm and preferably 3 mm;
    • e. drying the granulate at about 40-75° C. and preferably 55-65° C. inlet air temperature for example in a fluid bed dryer until the desired loss on drying value in the range of 1-5% is obtained;
    • f. delumping the dried granulate for example by sieving through a sieve with a mesh size of 0.6 mm-1.6 mm, preferably 1.0 mm; and
    • g. adding preferably sieved lubricant to the granulate for final blending for example in a cube mixer.
  • In an alternative process part of the exipients such as part of a disintegrant (e.g. corn starch) or a diluent (e.g. pregelatinized starch) or an additional disintegrant (crospovidone) can be added extragranular prior to final blending of step g.
  • In another alternative version of the process the granulate produced in steps a to e is produced in a one pot high shear granulation process and subsequent drying in a one pot granulator.
  • For the preparation of capsules the final blend is further filled into capsules.
  • For the preparation of tablets or tablet cores the final blend is further compressed into tablets of the target tablet core weight with appropriate size and crushing strength, using an appropriate tablet press.
  • For the preparation of film-coated tablets a coating suspension is prepared and the compressed tablet cores are coated with the coating suspension to a weight gain of about 2-4%, preferably about 3%, using a standard film coater. The film-coating solvent is a volatile component, which does not remain in the final product. To reduce the required amount of lubricant in the tablets it is an option to use an external lubrication system.
    • EXAMPLES Example 1 Formulation for Direct Compression
  • An active DPP IV inhibitor ingredient with a primary amino group and all other excipients with exception of magnesium stearate are blended in a high shear blender. This pre-mix is sieved through a 1 mm sieve. After addition of magnesium stearate the pre-mix is blended in a free fall blender to produce the final blend. The final blend is compressed into tablets using a suitable tablet press. The following compositions can be obtained:
  • Component mg/tablet %/tablet mg/tablet %/tablet
    Active ingredient 1.000 2.000 2.500 2.000
    Mannitol 43.250 86.500 108.125 86.500
    Pregelatinized starch 5.000 10.000 12.500 10.000
    Magnesium stearate 0.750 1.500 1.875 1.500
    Total 50.000 100.000 125.000 100.000
  • Component mg/tablet %/tablet mg/tablet %/tablet
    Active ingredient 5.000 2.000 10.000 2.000
    Mannitol 216.250 86.500 432.500 86.500
    Pregelatinized starch 25.000 10.000 50.000 10.000
    Magnesium stearate 3.750 1.500 7.500 1.500
    Total 250.000 100.000 500.000 100.000
    • Example 2 Alternative Formulation for Direct Compression
  • An active DPP IV inhibitor ingredient with a primary amino group and all other excipients with exception of magnesium stearate are blended in a high shear blender. This pre-mix is sieved through a 1 mm sieve. After addition of magnesium stearate the pre-mix is blended in a free fall blender to produce the final blend. The final blend is compressed into tablets using a suitable tablet press. The following compositions can be obtained:
  • Component mg/tablet %/tablet mg/tablet %/tablet
    Active ingredient 1.000 1.667 0.500 0.833
    Dibasic 46.400 77.333 46.900 78.177
    calciumphosphate,
    anhydrous
    Low-substituted 12.000 20.000 12.000 20.000
    hydroxypropylcellulose
    Magnesium stearate 0.600 1.000 0.600 1.000
    Total 60.000 100.000 60.000 100.000
  • Component mg/tablet %/tablet mg/tablet %/tablet
    Active ingredient 10.000 1.667 10.000 2.222
    Dibasic 464.000 77.333 344.000 76.788
    calciumphosphate,
    anhydrous
    Low-substituted 120.000 20.000 90.000 20.000
    hydroxypropylcellulose
    Magnesium stearate 6.000 1.000 6.000 1.000
    Total 600.000 100.000 450.000 100.000
    • Example 3 Tablet Formulation
  • Copovidone is dissolved in purified water at ambient temperature to produce a granulation liquid. An active DPP IV inhibitor ingredient with a primary amino group, mannitol and part of the pregelatinized starch are blended in a suitable mixer, to produce a pre-mix. The pre-mix is moistened with the granulation liquid and subsequently granulated. The moist granulate is optionally sieved through a sieve with a mesh size of 1.6-3.0 mm. The granulate is dried at 55° C. in a suitable dryer to a residual moisture content corresponding to 2-5% loss on drying. The dried granulate is sieved through a sieve with a mesh size of 1.0 mm. The granulate is blended with part of the pregelatinized starch in a suitable mixer. Magnesium stearate is added to this blend after passing through a 1.0 mm sieve for delumping. Subsequently the final blend is produced by final blending in a suitable mixer and compressed into tablets. The following tablet composition can be obtained:
  • Component mg/tablet %/tablet
    Active ingredient 10.000 1.667
    Pregelatinized starch 210.000 35.000
    Mannitol 236.000 39.333
    Copovidone 18.000 3.000
    Total (granulate) 474.000 79.000
    Pregelatinized starch 120.000 20.000
    Magnesium stearate 6.000 1.000
    Total 600.000 100.000
    • Example 4 Coated Tablet Formulation
  • Copovidone is dissolved in purified water at ambient temperature to produce a granulation liquid. An active DPP IV inhibitor ingredient with a primary amino group, mannitol, pregelatinized starch and corn starch are blended in a suitable mixer to produce the pre-mix. The pre-mix is moistened with the granulation liquid and subsequently granulated using a high shear mixer. The moist granulate is optionally sieved through a sieve with a mesh size of 1.6-3.0 mm. The granulate is dried at about 60° C. in a fluid bed dryer until a loss on the drying value of 2-4% is obtained. The Final Blend is compressed into tablet cores.
  • Hydroxypropyl methylcellulose, polyethylene glycol, talc, titanium dioxide and iron oxide are suspended in purified water in a suitable mixer at ambient temperature to produce a coating suspension. The tablet cores are coated with the coating suspension to a weight gain of about 3% to produce film-coated tablets. The following tablet compositions can be obtained:
  • Component mg mg mg mg mg
    Active ingredient 0.500 1.000 2.500 5.000 10.000
    Mannitol 67.450 66.950 65.450 130.900 125.900
    Pregelatinized starch 9.000 9.000 9.000 18.000 18.000
    Corn starch 9.000 9.000 9.000 18.000 18.000
    Copovidone 2.700 2.700 2.700 5.400 5.400
    Magnesium stearate 1.350 1.350 1.350 2.700 2.700
    Total Mass 90.000 90.000 90.000 180.000 180.000
    (tablet core)
    HPMC 1.500 1.500 1.500 2.500 2.500
    PEG 0.150 0.150 0.150 0.250 0.250
    Titanium dioxide 0.750 0.750 0.750 1.250 1.250
    Talc 0.525 0.525 0.525 0.875 0.875
    Iron oxide, yellow 0.075 0.075 0.075 0.125 0.125
    Total Mass 93.000 93.000 93.000 185.000 185.000
    (coated tablet)
    • Example 5 Tablet Formulation
  • Copovidone is dissolved in purified water at ambient temperature to produce a granulation liquid. An active DPP IV inhibitor ingredient with a primary amino group, mannitol and pregelatinized starch are blended in a suitable mixer to produce a pre-mix. The pre-mix is moistened with the granulation liquid and subsequently granulated. The moist granulate is optionally sieved through a suitable sieve. The granulate is dried at about 50° C. in a suitable dryer until a loss on drying value of 3-5% is obtained. The dried granulate is sieved through a sieve with a mesh size of 1.0 mm.
  • Magnesium stearate is passed through a 1.0 mm sieve and added to the granulate. Subsequently the final blend is produced by final blending in a suitable blender and the final blend is compressed into tablets. The following tablet compositions can be obtained:
  • Component mg mg mg mg mg
    Active ingredient 0.500 1.000 2.500 5.000 10.000
    Mannitol 27.500 27.000 67.500 135.000 130.000
    Pregelatinized starch 20.000 20.000 50.000 100.000 100.000
    Copovidone 1.500 1.500 3.750 7.500 7.500
    Magnesium stearate 0.500 0.500 1.250 2.500 2.500
    Total tablet mass 50.000 50.000 125.000 250.000 250.000
    • Example 6 Tablet Formulation Variants
  • Copovidone is dissolved in purified water at ambient temperature to produce a granulation liquid. An active DPP IV inhibitor ingredient with a primary amino group and a part of mannitol, pregelatinized starch and corn starch are blended in a suitable mixer, to produce a pre-mix. The pre-mix is moistened with the granulation liquid and subsequently granulated. The moist granulate is sieved through a suitable sieve. The granulate is dried at about 60° C. inlet air temperature in a fluid bed dryer until a loss on drying value of 1-4% is obtained. The dried granulate is sieved through a sieve with a mesh size of 1.0 mm.
  • Magnesium stearate is passed through a sieve for delumping and added to the granulate. Additionally the remaining part of the exipients are added extragranular at this process step. Subsequently the final blend is produced by final blending in a suitable blender and compressed into tablet cores.
  • Hydroxypropyl methylcellulose, polyethylene glycol, talc, titanium dioxide and iron oxide are suspended in purified water in a suitable mixer at ambient temperature to produce a coating suspension. The tablet cores are coated with the coating suspension to a weight gain of about 3% to produce film-coated tablets. The following formulation variants can be obtained:
    • Example 6.1 Formulation Variants with Extragranular Excipients
  • Formulation E Formulation F
    Component mg/Tablet %/Tablet mg/Tablet %/Tablet
    Active ingredient 1.000 1.111 1.000 1.111
    Mannitol 23.300 25.889 66.950 74.389
    Pregelatinized starch 4.500 5.000 4.500 5.000
    Corn starch 4.500 5.000 4.500 5.000
    Copovidone 1.350 1.500 2.700 3.000
    Total (granulate) 34.650 38.500 79.650 88.500
    Corn starch 4.500 5.000 4.500 5.000
    Pregelatinized starch 4.500 5.000 4.500 5.000
    Mannitol 45.000 50.000
    Magnesium stearate 1.350 1.500 1.350 1.500
    Total (tablet core) 90.000 100.000 90.000 100.000
    • Example 6.2 Formulation Variants with Additional Extragranular Disintegrant
  • Component mg mg mg mg mg
    Active ingredient 0.500 1.000 2.500 5.000 10.000
    Mannitol 67.450 66.950 65.450 130.900 125.900
    Pregelatinized starch 9.000 9.000 9.000 18.000 18.000
    Corn starch 9.000 9.000 9.000 18.000 18.000
    Copovidone 2.700 2.700 2.700 5.400 5.400
    Total Mass 88.650 88.650 88.650 177.300 177.300
    (granulate)
    Magnesium stearate 1.350 1.350 1.350 2.700 2.700
    Crospovidone 2.000 2.000 2.000 4.000 4.000
    Total Mass 92.000 92.000 92.000 184.000 184.000
    (tablet core)
    HPMC 1.500 1.500 1.500 2.500 2.500
    PEG 0.150 0.150 0.150 0.250 0.250
    Titanium dioxide 0.750 0.750 0.750 1.250 1.250
    Talc 0.525 0.525 0.525 0.875 0.875
    Iron oxide, yellow 0.075 0.075 0.075 0.125 0.125
    Total Mass 95.000 95.000 95.000 189.000 189.000
    (coated tablet)
    • Example 6.3 High Dose Formulations D
  • Component mg/tablet %/tablet mg/tablet %/tablet
    Active ingredient 25.000 27.778 50.000 27.778
    Mannitol 40.700 45.222 81.400 45.222
    Pregelatinized starch 9.000 10.000 18.000 10.000
    Corn starch 9.000 10.000 18.000 10.000
    Copovidone 2.700 3.000 5.400 3.000
    Total (granulate) 86.400 96.000 172.800 96.000
    Crospovidone 2.700 3.000 5.400 3.000
    Magnesium stearate 0.900 1.000 1.800 1.000
    Total (tablet core) 90.000 100.000 180.000 100.000
    Hydroxypropyl 1.500 1.667 2.500 1.389
    methylcellulose
    Polyethylene glycol 0.150 0.167 0.250 0.139
    Titanium dioxide 0.750 0.833 1.250 0.694
    Talcum 0.525 0.583 0.875 0.486
    Iron oxide yellow 0.075 0.083 0.125 0.069
    Total 93.000 103.333 185.000 102.778
    (film-coated tablet)

Claims (22)

1. A pharmaceutical composition comprising as an active ingredient a DPP IV inhibitor compound of formula
Figure US20120003313A1-20120105-C00015
in an amount of 0.5 mg, 1 mg, 2.5 mg, 5 mg or 10 mg, or a salt thereof, a first diluent, a second diluent, a binder, a disintegrant and a lubricant, wherein the first diluent is mannitol, the second diluent is pregelatinized starch, the binder is copovidone, the disintegrant is corn starch, and the lubricant is magnesium stearate; and wherein the DPP IV inhibitor compound is present in an amount 0.5-20% based on the total weight of DPP IV inhibitor compound, first diluent, second diluent, binder, disintegrant and lubricant.
2. The pharmaceutical composition of claim 1 further comprising an additional disintegrant.
3. The pharmaceutical composition of claim 2, wherein the additional disintegrant is crospovidone.
4. The pharmaceutical composition of claim 1 further comprising a glidant.
5. The pharmaceutical composition of claim 4, wherein the glidant is colloidal silicon dioxide.
6. The pharmaceutical composition of claim 1 comprising
40-88%  diluent 1, 3-40% diluent 2,  1-5% binder, 5-15% disintegrant, and 0.1-4%  lubricant
7. The pharmaceutical composition of claim 1 comprising
0.5-7% active ingredient 50-75%  diluent 1,  5-15% diluent 2,  2-4% binder,  8-12% disintegrant, and 0.5-2% lubricant
8. The pharmaceutical composition according to claim 1 in the dosage form of a capsule, a tablet, or a film-coated tablet.
9. The pharmaceutical composition of claim 8 comprising 2-4% film coat.
10. The pharmaceutical composition of claim 9, wherein the film coat comprises a film-forming agent, a plasticizer, a glidant and optionally one or more pigments.
11. The pharmaceutical composition of claim 10, wherein the film coat comprises hydroxypropylmethylcellulose (HPMC), polyethylene glycol (PEG), talc, titanium dioxide and iron oxide.
12. A process for the preparation of a pharmaceutical composition according to claim 1 comprising
a. dissolving the binder in a solvent to produce a granulation liquid;
b. blending the DPP-IV inhibitor, a diluent, and the disintegrant to produce a pre-mix;
c. moistening the pre-mix with the granulation liquid and subsequently granulating the moistened pre-mix;
d. optionally sieving the granulated pre-mix through a sieve with a mesh size of at least 1.0 mm;
e. drying the granulate at about 40-75° C. until the desired loss on drying value in the range of 1-5% is obtained;
f. sieving the dried granulate through a sieve with a mesh size of at least 0.6 mm;
g. adding the lubricant to the granulate for final blending.
13. The process according to claim 12 further comprising
h. compressing the final blend into tablet cores;
i. preparing a coating suspension;
j. coating the tablet cores with the coating suspension to a weight gain of about 2-4% to produce film-coated tablets.
14. The process according to claim 12, wherein part of the excipients are added extragranular prior to the final blending of step g.
15. The process according to claim 12, wherein the granulate produced in steps a-e is produced in a one pot high shear granulation process and subsequent drying in a one pot granulator.
16. The pharmaceutical composition according to claim 1, wherein 1-[(4-methyl-quinazolin-2-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-(3-(R)-amino-piperidin-1-yl)-xanthine is comprised in an amount of 5 mg.
17. The pharmaceutical composition according to claim 16 in the form of a capsule, a tablet, or a film-coated tablet.
18. The pharmaceutical composition of claim 16, wherein the composition is in the form of a film-coated tablet, and wherein the film coat comprise 2-4% wt % based the weight of the uncoated tablet.
19. The pharmaceutical composition of claim 18, wherein the film coat comprises a film-forming agent, a plasticizer, a glidant and optionally one or more pigments.
20. The pharmaceutical composition of claim 19, wherein the film coat comprises hydroxypropylmethylcellulose (HPMC), polyethylene glycol (PEG), talc, titanium dioxide and iron oxide.
21. The pharmaceutical composition according to claim 16, which is an oral dosage form in the form of a tablet.
22. The pharmaceutical composition according to claim 16, which is an oral dosage form in form of a film-coated tablet.
US13/230,133 2006-05-04 2011-09-12 Dpp iv inhibitor formulations Abandoned US20120003313A1 (en)

Priority Applications (8)

Application Number Priority Date Filing Date Title
US13/230,133 US20120003313A1 (en) 2006-05-04 2011-09-12 Dpp iv inhibitor formulations
US13/467,505 US20120219622A1 (en) 2006-05-04 2012-05-09 Dpp iv inhibitor formulations
US13/735,078 US20130122089A1 (en) 2006-05-04 2013-01-07 Dpp iv inhibitor formulations
US14/877,019 US20160022687A1 (en) 2006-05-04 2015-10-07 Dpp iv inhibitor formulations
US15/655,269 US20170312287A1 (en) 2006-05-04 2017-07-20 Dpp iv inhibitor formulations
US16/357,357 US11033552B2 (en) 2006-05-04 2019-03-19 DPP IV inhibitor formulations
US17/319,325 US12178819B2 (en) 2006-05-04 2021-05-13 DPP IV inhibitor formulations
US18/944,220 US20250064818A1 (en) 2006-05-04 2024-11-12 Dpp iv inhibitor formulations

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP06009201A EP1852108A1 (en) 2006-05-04 2006-05-04 DPP IV inhibitor formulations
EP06009201 2006-05-04
US11/744,701 US20080107731A1 (en) 2006-05-04 2007-05-04 Dpp iv inhibitor formulations
US13/230,133 US20120003313A1 (en) 2006-05-04 2011-09-12 Dpp iv inhibitor formulations

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US11/744,701 Continuation US20080107731A1 (en) 2006-05-04 2007-05-04 Dpp iv inhibitor formulations

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US13/467,505 Continuation US20120219622A1 (en) 2006-05-04 2012-05-09 Dpp iv inhibitor formulations

Publications (1)

Publication Number Publication Date
US20120003313A1 true US20120003313A1 (en) 2012-01-05

Family

ID=36972901

Family Applications (9)

Application Number Title Priority Date Filing Date
US11/744,701 Abandoned US20080107731A1 (en) 2006-05-04 2007-05-04 Dpp iv inhibitor formulations
US13/230,133 Abandoned US20120003313A1 (en) 2006-05-04 2011-09-12 Dpp iv inhibitor formulations
US13/467,505 Abandoned US20120219622A1 (en) 2006-05-04 2012-05-09 Dpp iv inhibitor formulations
US13/735,078 Abandoned US20130122089A1 (en) 2006-05-04 2013-01-07 Dpp iv inhibitor formulations
US14/877,019 Abandoned US20160022687A1 (en) 2006-05-04 2015-10-07 Dpp iv inhibitor formulations
US15/655,269 Abandoned US20170312287A1 (en) 2006-05-04 2017-07-20 Dpp iv inhibitor formulations
US16/357,357 Active US11033552B2 (en) 2006-05-04 2019-03-19 DPP IV inhibitor formulations
US17/319,325 Active US12178819B2 (en) 2006-05-04 2021-05-13 DPP IV inhibitor formulations
US18/944,220 Pending US20250064818A1 (en) 2006-05-04 2024-11-12 Dpp iv inhibitor formulations

Family Applications Before (1)

Application Number Title Priority Date Filing Date
US11/744,701 Abandoned US20080107731A1 (en) 2006-05-04 2007-05-04 Dpp iv inhibitor formulations

Family Applications After (7)

Application Number Title Priority Date Filing Date
US13/467,505 Abandoned US20120219622A1 (en) 2006-05-04 2012-05-09 Dpp iv inhibitor formulations
US13/735,078 Abandoned US20130122089A1 (en) 2006-05-04 2013-01-07 Dpp iv inhibitor formulations
US14/877,019 Abandoned US20160022687A1 (en) 2006-05-04 2015-10-07 Dpp iv inhibitor formulations
US15/655,269 Abandoned US20170312287A1 (en) 2006-05-04 2017-07-20 Dpp iv inhibitor formulations
US16/357,357 Active US11033552B2 (en) 2006-05-04 2019-03-19 DPP IV inhibitor formulations
US17/319,325 Active US12178819B2 (en) 2006-05-04 2021-05-13 DPP IV inhibitor formulations
US18/944,220 Pending US20250064818A1 (en) 2006-05-04 2024-11-12 Dpp iv inhibitor formulations

Country Status (36)

Country Link
US (9) US20080107731A1 (en)
EP (5) EP1852108A1 (en)
JP (8) JP5478244B2 (en)
KR (5) KR102051281B1 (en)
CN (2) CN101437493B (en)
AR (2) AR060755A1 (en)
AT (1) ATE480228T1 (en)
AU (1) AU2007247193B2 (en)
BR (2) BRPI0722388B1 (en)
CA (1) CA2649922C (en)
CL (2) CL2012002521A1 (en)
CY (2) CY1111354T1 (en)
DE (1) DE602007009091D1 (en)
DK (3) DK2283819T3 (en)
EA (2) EA029890B1 (en)
EC (1) ECSP088800A (en)
ES (3) ES2348576T3 (en)
HR (2) HRP20100507T1 (en)
HU (1) HUE025210T2 (en)
IL (2) IL195030A (en)
ME (2) ME01170B (en)
MX (3) MX2008013958A (en)
MY (2) MY146969A (en)
NO (1) NO343067B1 (en)
NZ (3) NZ613426A (en)
PE (2) PE20080698A1 (en)
PL (3) PL2283819T3 (en)
PT (2) PT2023902E (en)
RS (2) RS53570B1 (en)
SG (1) SG171649A1 (en)
SI (2) SI2023902T1 (en)
TW (2) TWI474843B (en)
UA (1) UA94942C2 (en)
UY (1) UY30319A1 (en)
WO (1) WO2007128724A1 (en)
ZA (1) ZA200808361B (en)

Cited By (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8178541B2 (en) 2002-08-21 2012-05-15 Boehringer Ingelheim Pharma Gmbh & Co. Kg 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
US8232281B2 (en) 2006-05-04 2012-07-31 Boehringer Ingelheim International Gmbh Uses of DPP-IV inhibitors
US8513264B2 (en) 2008-09-10 2013-08-20 Boehringer Ingelheim International Gmbh Combination therapy for the treatment of diabetes and related conditions
US8541450B2 (en) 2004-11-05 2013-09-24 Boehringer Ingelheim International Gmbh Process for the preparation of chiral 8-(3-aminopiperidin-1yl)-xanthines
US8551957B2 (en) 2007-08-16 2013-10-08 Boehringer Ingelheim International Gmbh Pharmaceutical composition comprising a glucopyranosyl-substituted benzene derivate
US8637530B2 (en) 2005-07-30 2014-01-28 Boehringer Ingelheim International Gmbh 8-(3-amino-piperidin-1-yl)-xanthines, their preparation, and their use as pharmaceuticals
US8697868B2 (en) 2004-02-18 2014-04-15 Boehringer Ingelheim International Gmbh 8-[3-amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical compositions
WO2014080384A1 (en) 2012-11-26 2014-05-30 Ranbaxy Laboratories Limited Pharmaceutical composition of linagliptin
US8846695B2 (en) 2009-01-07 2014-09-30 Boehringer Ingelheim International Gmbh Treatment for diabetes in patients with inadequate glycemic control despite metformin therapy comprising a DPP-IV inhibitor
US8853156B2 (en) 2008-08-06 2014-10-07 Boehringer Ingelheim International Gmbh Treatment for diabetes in patients inappropriate for metformin therapy
US8865729B2 (en) 2008-12-23 2014-10-21 Boehringer Ingelheim International Gmbh Salt forms of a xanthine compound
US8883800B2 (en) 2011-07-15 2014-11-11 Boehringer Ingelheim International Gmbh Substituted quinazolines, the preparation thereof and the use thereof in pharmaceutical compositions
US9034883B2 (en) 2010-11-15 2015-05-19 Boehringer Ingelheim International Gmbh Vasoprotective and cardioprotective antidiabetic therapy
US9149478B2 (en) 2010-06-24 2015-10-06 Boehringer Ingelheim International Gmbh Diabetes therapy
US9155705B2 (en) 2008-04-03 2015-10-13 Boehringer Ingelheim International Gmbh DPP-IV inhibitor combined with a further antidiabetic agent, tablets comprising such formulations, their use and process for their preparation
US9186392B2 (en) 2010-05-05 2015-11-17 Boehringer Ingelheim International Gmbh Combination therapy
US9266888B2 (en) 2006-05-04 2016-02-23 Boehringer Ingelheim International Gmbh Polymorphs
US9457029B2 (en) 2009-11-27 2016-10-04 Boehringer Ingelheim International Gmbh Treatment of genotyped diabetic patients with DPP-IV inhibitors such as linagliptin
US9486526B2 (en) 2008-08-06 2016-11-08 Boehringer Ingelheim International Gmbh Treatment for diabetes in patients inappropriate for metformin therapy
US9526728B2 (en) 2014-02-28 2016-12-27 Boehringer Ingelheim International Gmbh Medical use of a DPP-4 inhibitor
US9526730B2 (en) 2012-05-14 2016-12-27 Boehringer Ingelheim International Gmbh Use of a DPP-4 inhibitor in podocytes related disorders and/or nephrotic syndrome
US9555001B2 (en) 2012-03-07 2017-01-31 Boehringer Ingelheim International Gmbh Pharmaceutical composition and uses thereof
EP3156048A1 (en) 2015-10-13 2017-04-19 Galenicum Health S.L. Stable pharmaceutical composition of linagliptin in the form of immediate release tablets
US9713618B2 (en) 2012-05-24 2017-07-25 Boehringer Ingelheim International Gmbh Method for modifying food intake and regulating food preference with a DPP-4 inhibitor
US20180185291A1 (en) 2011-03-07 2018-07-05 Boehringer Ingelheim International Gmbh Pharmaceutical compositions
US10155000B2 (en) 2016-06-10 2018-12-18 Boehringer Ingelheim International Gmbh Medical use of pharmaceutical combination or composition
US10406172B2 (en) 2009-02-13 2019-09-10 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
US11033552B2 (en) 2006-05-04 2021-06-15 Boehringer Ingelheim International Gmbh DPP IV inhibitor formulations
US11911388B2 (en) 2008-10-16 2024-02-27 Boehringer Ingelheim International Gmbh Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral or non-oral antidiabetic drug
US12312352B2 (en) 2012-05-14 2025-05-27 Boehringer Ingelheim International Gmbh Use of a DPP-4 inhibitor in SIRS and/or sepsis

Families Citing this family (88)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2530113B2 (en) 1994-06-29 1996-09-04 インターナショナル・ビジネス・マシーンズ・コーポレイション Interface circuit for data transfer control and magnetic disk device
US7495005B2 (en) * 2002-08-22 2009-02-24 Boehringer Ingelheim Pharma Gmbh & Co. Kg Xanthine derivatives, their preparation and their use in pharmaceutical compositions
US7482337B2 (en) * 2002-11-08 2009-01-27 Boehringer Ingelheim Pharma Gmbh & Co. Kg Xanthine derivatives, the preparation thereof and their use as pharmaceutical compositions
US7439370B2 (en) 2004-05-10 2008-10-21 Boehringer Ingelheim International Gmbh Imidazole derivatives, their preparation and their use as intermediates for the preparation of pharmaceutical compositions and pesticides
DE102004030502A1 (en) 2004-06-24 2006-01-12 Boehringer Ingelheim Pharma Gmbh & Co. Kg Novel imidazoles and triazoles, their preparation and use as medicines
US7772191B2 (en) 2005-05-10 2010-08-10 Boehringer Ingelheim International Gmbh Processes for preparing of glucopyranosyl-substituted benzyl-benzene derivatives and intermediates therein
JP5453086B2 (en) 2006-06-06 2014-03-26 イントラ−セルラー・セラピーズ・インコーポレイテッド Organic compounds
EP2057160A1 (en) 2006-08-08 2009-05-13 Boehringer Ingelheim International GmbH Pyrrolo [3, 2 -d]pyrimidines as dpp-iv inhibitors for the treatment of diabetes mellitus
EP2025674A1 (en) 2007-08-15 2009-02-18 sanofi-aventis Substituted tetra hydro naphthalines, method for their manufacture and their use as drugs
ES2588238T3 (en) 2007-12-06 2016-10-31 Intra-Cellular Therapies, Inc. Derivatives of pyrazolopyrimidin-4,6-dione and its use as a pharmaceutical product
EP2327406A4 (en) * 2008-08-14 2014-04-09 Kyorin Seiyaku Kk STABILIZED PHARMACEUTICAL COMPOSITION
AU2009281122C1 (en) 2008-08-15 2016-04-21 Boehringer Ingelheim International Gmbh Purin derivatives for use in the treatment of fab-related diseases
JP5694773B2 (en) * 2008-09-30 2015-04-01 テバ製薬株式会社 COMPRESSION MOLDED PREPARATION AND METHOD
MA32941B1 (en) 2008-12-06 2012-01-02 Intra Cellular Therapies Inc Organic compounds
WO2010065147A1 (en) 2008-12-06 2010-06-10 Intra-Cellular Therapies, Inc. Organic compounds
WO2010065153A1 (en) 2008-12-06 2010-06-10 Intra-Cellular Therapies, Inc. Organic compounds
US8404727B2 (en) 2009-01-07 2013-03-26 Glenmark Pharmaceuticals S.A. Pharmaceutical composition that includes a dipeptidyl peptidase-IV inhibitor
TWI466672B (en) 2009-01-29 2015-01-01 Boehringer Ingelheim Int Treatment for diabetes in paediatric patients
UY32427A (en) * 2009-02-13 2010-09-30 Boheringer Ingelheim Internat Gmbh PHARMACEUTICAL COMPOSITION, PHARMACEUTICAL FORM, PROCEDURE FOR PREPARATION, METHODS OF TREATMENT AND USES OF THE SAME
MX2011008416A (en) * 2009-02-13 2011-09-08 Boehringer Ingelheim Int Antidiabetic medications comprising a dpp-4 inhibitor (linagliptin) optionally in combination with other antidiabetics.
MX342330B (en) 2009-05-19 2016-09-26 Celgene Corp Formulations of 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1 ,3-dione.
EA020798B1 (en) 2009-09-30 2015-01-30 Бёрингер Ингельхайм Интернациональ Гмбх Method for the preparation of a crystalline form of 1-chloro-4-(beta-d-glucopyranos-1-yl)-2-[4-((s)-tetrahydrofuran-3-yloxy)benzyl]benzene
PL2486029T3 (en) 2009-09-30 2015-11-30 Boehringer Ingelheim Int Processes for preparing of glucopyranosyl-substituted benzyl-benzene derivatives
UY32919A (en) 2009-10-02 2011-04-29 Boehringer Ingelheim Int Pharmaceutical composition, pharmaceutical dosage form, procedure for its preparation, methods for its treatment and its uses
BR112012007234A2 (en) 2009-10-02 2016-04-05 Boehringer Ingelheim Int pharmaceutical combination comprising dpp-4 inhibitor and metformin, as well as their use and preparation process
JP5775463B2 (en) * 2009-12-18 2015-09-09 田辺三菱製薬株式会社 Elution stability formulation
WO2011107494A1 (en) 2010-03-03 2011-09-09 Sanofi Novel aromatic glycoside derivatives, medicaments containing said compounds, and the use thereof
JP5031054B2 (en) * 2010-03-18 2012-09-19 信越化学工業株式会社 Low substituted hydroxypropyl cellulose and solid preparation containing the same
WO2011113947A1 (en) 2010-03-18 2011-09-22 Boehringer Ingelheim International Gmbh Combination of a gpr119 agonist and the dpp-iv inhibitor linagliptin for use in the treatment of diabetes and related conditions
KR20130069615A (en) * 2010-05-05 2013-06-26 베링거 인겔하임 인터내셔날 게엠베하 Pharmaceutical formulations comprising pioglitazone and linagliptin
JP5894148B2 (en) 2010-05-31 2016-03-23 イントラ−セルラー・セラピーズ・インコーポレイテッドＩｎｔｒａ−Ｃｅｌｌｕｌａｒ Ｔｈｅｒａｐｉｅｓ， Ｉｎｃ． Organic compounds
US9434730B2 (en) 2010-05-31 2016-09-06 Intra-Cellular Therapies, Inc. PDE1 inhibitor compounds
WO2011157827A1 (en) 2010-06-18 2011-12-22 Sanofi Azolopyridin-3-one derivatives as inhibitors of lipases and phospholipases
US8530413B2 (en) 2010-06-21 2013-09-10 Sanofi Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
TW201215388A (en) 2010-07-05 2012-04-16 Sanofi Sa (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
TW201221505A (en) 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
TW201215387A (en) 2010-07-05 2012-04-16 Sanofi Aventis Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
WO2012120054A1 (en) 2011-03-08 2012-09-13 Sanofi Di- and tri-substituted oxathiazine derivates, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
WO2012120056A1 (en) 2011-03-08 2012-09-13 Sanofi Tetrasubstituted oxathiazine derivatives, method for producing them, their use as medicine and drug containing said derivatives and the use thereof
EP2766349B1 (en) 2011-03-08 2016-06-01 Sanofi Oxathiazine derivatives substituted with carbocycles or heterocycles, method for producing same, drugs containing said compounds, and use thereof
US8828995B2 (en) 2011-03-08 2014-09-09 Sanofi Branched oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
US8710050B2 (en) 2011-03-08 2014-04-29 Sanofi Di and tri- substituted oxathiazine derivatives, method for the production, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
US8785455B2 (en) 2011-05-10 2014-07-22 Sandoz Ag Polymorph of linagliptin benzoate
WO2012170702A1 (en) 2011-06-08 2012-12-13 Arena Pharmaceuticals, Inc. Modulators of the gpr119 receptor and the treatment of disorders related thereto
WO2013037390A1 (en) 2011-09-12 2013-03-21 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
WO2013045413A1 (en) 2011-09-27 2013-04-04 Sanofi 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
US20130172244A1 (en) 2011-12-29 2013-07-04 Thomas Klein Subcutaneous therapeutic use of dpp-4 inhibitor
US9192617B2 (en) 2012-03-20 2015-11-24 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
WO2013174768A1 (en) 2012-05-24 2013-11-28 Boehringer Ingelheim International Gmbh A xanthine derivative as dpp -4 inhibitor for use in the treatment of autoimmune diabetes, particularly lada
JP2015518843A (en) 2012-05-25 2015-07-06 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Use of keratinocytes as bioactive agents that may be combined with DPP-4 inhibitors in the treatment of wounds, for example diabetic wounds
KR102145641B1 (en) 2012-06-05 2020-08-18 다케다 야쿠힌 고교 가부시키가이샤 Solid preparation
CA2879003C (en) 2012-08-13 2020-09-22 Sandoz Ag Stable pharmaceutical composition containing 8-[(3r)-3-amino-1-piperidinyl]-7-(2-butyn-1-yl)-3,7-dihydro-3-methyl-1-[(4-methyl-2-quinazolinyl)methyl]-1h-purine-2,6-dione or a pharmaceutically acceptable salt thereof
US20150246117A1 (en) 2012-09-24 2015-09-03 Ulf Eriksson Treatment of type 2 diabetes and related conditions
WO2014051024A1 (en) * 2012-09-27 2014-04-03 株式会社 三和化学研究所 Anagliptin-containing drug composition
KR20150059720A (en) * 2012-09-27 2015-06-02 가부시키가이샤산와카가쿠켄큐쇼 Anagliptin-containing preparations
WO2014051025A1 (en) * 2012-09-27 2014-04-03 株式会社 三和化学研究所 Anagliptin-containing solid preparation
EP2911655A1 (en) 2012-10-24 2015-09-02 INSERM (Institut National de la Santé et de la Recherche Médicale) Tpl2 kinase inhibitors for preventing or treating diabetes and for promoting -cell survival
WO2014065427A1 (en) * 2012-10-26 2014-05-01 株式会社 三和化学研究所 Anagliptin-containing solid pharmaceutical preparation
WO2014140284A1 (en) 2013-03-15 2014-09-18 Boehringer Ingelheim International Gmbh Use of linagliptin in cardio- and renoprotective antidiabetic therapy
HK1213818A1 (en) 2013-04-05 2016-07-15 勃林格殷格翰国际有限公司 Therapeutic uses of empagliflozin
CA2812519A1 (en) 2013-04-05 2014-10-05 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
US11813275B2 (en) 2013-04-05 2023-11-14 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
HRP20190101T1 (en) 2013-04-05 2019-03-08 Boehringer Ingelheim International Gmbh THERAPEUTIC USES OF EMPAGLIFLOZINE
HK1215378A1 (en) 2013-04-18 2016-08-26 勃林格殷格翰国际有限公司 Pharmaceutical composition, methods for treating and uses thereof
EP2848241A1 (en) 2013-09-12 2015-03-18 Sanovel Ilac Sanayi ve Ticaret A.S. Effervescent formulations of linagliptin
EP2848242A1 (en) 2013-09-12 2015-03-18 Sanovel Ilac Sanayi ve Ticaret A.S. Orally disintegrating formulations of Linagliptin
TR201310724A2 (en) 2013-09-12 2015-03-23 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Pharmaceutical formulati̇ons of linagliptin
WO2015110962A1 (en) 2014-01-21 2015-07-30 Wockhardt Limited Solid oral pharmaceutical compositions comprising fixed dose combination of metformin and linagliptin or salts thereof
US20150283248A1 (en) * 2014-04-02 2015-10-08 Aurobindo Pharma Ltd. Pharmaceutical compositions of Linagliptin and process for preparation thereof
US9546175B2 (en) 2014-08-07 2017-01-17 Intra-Cellular Therapies, Inc. Organic compounds
CN105878349A (en) * 2014-11-28 2016-08-24 于凯 Composition for preventing and treating osteoporosis caused by diabetics
ES2805743T3 (en) 2015-03-24 2021-02-15 Inst Nat Sante Rech Med Method and pharmaceutical composition for use in the treatment of diabetes
CN107810005B (en) * 2015-06-17 2021-04-20 赫克萨尔股份公司 alogliptin preparations
EA037498B1 (en) 2015-10-09 2021-04-05 Хексаль Аг Pharmaceutical composition containing 8-[(3r)-3-amino-1-piperidinyl]-7-(2-butyn-1-yl)-3,7-dihydro-3-methyl-1-[4-methyl-2-quinazolinyl)methyl]-1h-purine-2,6-dione or a pharmaceutically acceptable salt thereof
US9727330B2 (en) * 2015-11-25 2017-08-08 Red Hat, Inc. Source to image transformation pipeline for a platform-as-a-service system
CN105853382B (en) * 2016-05-19 2019-07-19 广州迈达康医药科技有限公司 A kind of Li Gelieting oral disintegrating tablet and preparation method thereof
CN106236754A (en) * 2016-07-31 2016-12-21 合肥远志医药科技开发有限公司 A kind of compositions comprising Li Gelieting active component and preparation method thereof
CN106137991A (en) * 2016-08-01 2016-11-23 合肥远志医药科技开发有限公司 A kind of Li Gelieting sheet method of granulating
US20180125813A1 (en) 2016-11-10 2018-05-10 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
US11285180B2 (en) 2016-12-06 2022-03-29 Inserm (Institut National De La Sante Et De La Recherche Medicale) Methods of enhancing the potency of incretin-based drugs in subjects in need thereof
WO2020009675A2 (en) * 2018-06-01 2020-01-09 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Solid oral pharmaceutical compositions of linagliptin
MX2021003944A (en) * 2018-10-05 2021-07-16 Isp Investments Llc Smooth high solids film coating composition comprising water soluble cellulose ether, process for preparing the same.
WO2021076066A1 (en) 2019-10-14 2021-04-22 Santa Farma İlaç Sanayi̇ A.Ş. Oral formulations comprising sitagliptin hci monohydrate with improved pharmaceutical characteristics
CN113423404B (en) * 2019-12-02 2023-09-29 成都苑东生物制药股份有限公司 Xanthine derivative pharmaceutical composition and preparation method thereof
EP4373482B1 (en) 2021-07-22 2025-04-30 KRKA, D.D., Novo Mesto Process for preparing a pharmaceutical composition comprising linagliptin and metformin hydrochloride
KR20230126664A (en) 2022-02-23 2023-08-30 주식회사 제뉴원사이언스 Pharmaceutical combination of controlled drug delivery comprising linagliptin or a pharmaceutically acceptable salt thereof and metformin or a pharmaceutically acceptable salt thereof
CN115227661B (en) * 2022-09-22 2022-12-13 北京惠之衡生物科技有限公司 Linagliptin tablet and preparation method thereof
EP4608388A1 (en) 2022-10-25 2025-09-03 Starrock Pharma Inc. Combinatorial, and rotational combinatorial therapies for obesity and other diseases

Family Cites Families (498)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2056046A (en) * 1933-05-19 1936-09-29 Rhone Poulenc Sa Manufacture of bases derived from benz-dioxane
US2375138A (en) * 1942-05-01 1945-05-01 American Cyanamid Co Alkamine esters of aryloxymethyl benzoic acid
US2629736A (en) * 1951-02-24 1953-02-24 Searle & Co Basically substituted n-alkyl derivatives of alpha, beta, beta-triarylpropionamides
US2730544A (en) * 1952-07-23 1956-01-10 Sahyun Lab Alkylaminoalkyl esters of hydroxycyclohexylbenzoic acid
US2750387A (en) * 1953-11-25 1956-06-12 Searle & Co Basically substituted derivatives of diarylaminobenzamides
DE1211359B (en) * 1955-11-29 1966-02-24 Oreal Oxidant-free cold dye for human hair
US2928833A (en) * 1959-03-03 1960-03-15 S E Massengill Company Theophylline derivatives
US3174901A (en) * 1963-01-31 1965-03-23 Jan Marcel Didier Aron Samuel Process for the oral treatment of diabetes
US3454635A (en) * 1965-07-27 1969-07-08 Hoechst Ag Benzenesulfonyl-ureas and process for their manufacture
US3673241A (en) * 1968-04-04 1972-06-27 Ciba Geigy Corp Substituted benzaldehyde guanylhydrazones
ES385302A1 (en) 1970-10-22 1973-04-16 Miquel S A Lab Procedure for the obtaining of trisused derivatives of etilendiamine. (Machine-translation by Google Translate, not legally binding)
DE2205815A1 (en) 1972-02-08 1973-08-16 Hoechst Ag N-(oxazolin-2-yl)-piperazine - with antitussive activity
JPS5512435B2 (en) * 1972-07-01 1980-04-02
US4005208A (en) * 1975-05-16 1977-01-25 Smithkline Corporation N-Heterocyclic-9-xanthenylamines
US4061753A (en) 1976-02-06 1977-12-06 Interx Research Corporation Treating psoriasis with transient pro-drug forms of xanthine derivatives
AU508480B2 (en) 1977-04-13 1980-03-20 Asahi Kasei Kogyo Kabushiki Kaisha Microcrystalline cellulose excipient and pharmaceutical composition containing thesame
DE2758025A1 (en) 1977-12-24 1979-07-12 Bayer Ag Tri:hydroxy-piperidine derivs. - useful as glucosidase inhibitors for treating diabetes etc. and as animal feed additives
NO154918C (en) 1977-08-27 1987-01-14 Bayer Ag ANALOGUE PROCEDURE FOR THE PREPARATION OF THERAPEUTIC ACTIVE DERIVATIVES OF 3,4,5-TRIHYDROXYPIPERIDINE.
DE2929596A1 (en) 1979-07-21 1981-02-05 Hoechst Ag METHOD FOR PRODUCING OXOALKYL XANTHINES
CY1306A (en) 1980-10-01 1985-12-06 Glaxo Group Ltd Aminoalkyl furan derivative
US4382091A (en) 1981-04-30 1983-05-03 Syntex (U.S.A.) Inc. Stabilization of 1-substituted imidazole derivatives in talc
FR2558162B1 (en) 1984-01-17 1986-04-25 Adir NOVEL XANTHINE DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
FI79107C (en) * 1984-06-25 1989-11-10 Orion Yhtymae Oy Process for the preparation of stable form of prazosin hydrochloride.
JPS6130567A (en) 1984-07-23 1986-02-12 Shiseido Co Ltd Method of stabilizing urea
JPS61124383A (en) 1984-11-16 1986-06-12 Unitika Ltd Stabilization of immobilized fibrinolytic enzyme
AR240698A1 (en) * 1985-01-19 1990-09-28 Takeda Chemical Industries Ltd Process for the preparation of 5-(4-(2-(5-ethyl-2-pyridil)-ethoxy)benzyl)-2,4-thiazolodinedione and their salts
CA1242699A (en) 1985-02-01 1988-10-04 Bristol-Myers Company Cefbuperazone and derivatives thereof
GB8515934D0 (en) * 1985-06-24 1985-07-24 Janssen Pharmaceutica Nv (4-piperidinomethyl and-hetero)purines
US5258380A (en) * 1985-06-24 1993-11-02 Janssen Pharmaceutica N.V. (4-piperidinylmethyl and -hetero)purines
EP0223403B1 (en) 1985-10-25 1993-08-04 Beecham Group Plc Piperidine derivative, its preparation, and its use as medicament
US5034225A (en) 1985-12-17 1991-07-23 Genentech Inc. Stabilized human tissue plasminogen activator compositions
US5433959A (en) 1986-02-13 1995-07-18 Takeda Chemical Industries, Ltd. Stabilized pharmaceutical composition
EP0237608B1 (en) 1986-03-21 1992-01-29 HEUMANN PHARMA GMBH & CO Crystalline anhydrous sigma-form of 2-[4-(2-furoyl-(2-piperazin)-1-yl]-4-amino-6,7-dimethoxyquinazoline hydrochloride, and process for its preparation
WO1987006941A1 (en) 1986-05-05 1987-11-19 The General Hospital Corporation Insulinotropic hormone
US5120712A (en) 1986-05-05 1992-06-09 The General Hospital Corporation Insulinotropic hormone
AU619444B2 (en) 1986-06-02 1992-01-30 Nippon Chemiphar Co. Ltd. 2-(2-aminobenzylsulfinyl)- benzimidazole derivatives
US4968672A (en) 1987-01-02 1990-11-06 The United States Of America As Represented By The Department Of Health And Human Services Adenosine receptor prodrugs
US4743450A (en) 1987-02-24 1988-05-10 Warner-Lambert Company Stabilized compositions
JPS63273159A (en) 1987-04-30 1988-11-10 Sharp Corp character processing device
JPS6440433A (en) 1987-08-05 1989-02-10 Green Cross Corp Aqueous liquid composition of thrombin
DE68920773T2 (en) 1988-05-19 1995-05-18 Chugai Pharmaceutical Co Ltd Quinolonecarboxylic acid derivatives.
US5329025A (en) * 1988-09-21 1994-07-12 G. D. Searle & Co. 3-azido compound
US5234897A (en) * 1989-03-15 1993-08-10 Bayer Aktiengesellschaft Herbicidal 3-amino-5-aminocarbonyl-1,2,4-triazoles
DE3926119A1 (en) 1989-08-08 1991-02-14 Bayer Ag 3-AMINO-5-AMINOCARBONYL-1,2,4-TRIAZOLE DERIVATIVES
GB8906792D0 (en) 1989-03-23 1989-05-10 Beecham Wuelfing Gmbh & Co Kg Treatment and compounds
DE3916430A1 (en) 1989-05-20 1990-11-22 Bayer Ag METHOD FOR PRODUCING 3-AMINO-5-AMINOCARBONYL-1,2,4-TRIAZOLE DERIVATIVES
IL94390A (en) 1989-05-30 1996-03-31 Merck & Co Inc Di-substituted imidazo fused 6-membered nitrogen-containing heterocycles and pharmaceutical compositions containing them
US5332744A (en) * 1989-05-30 1994-07-26 Merck & Co., Inc. Substituted imidazo-fused 6-membered heterocycles as angiotensin II antagonists
US5223499A (en) * 1989-05-30 1993-06-29 Merck & Co., Inc. 6-amino substituted imidazo[4,5-bipyridines as angiotensin II antagonists
FI94339C (en) 1989-07-21 1995-08-25 Warner Lambert Co Process for the preparation of pharmaceutically acceptable [R- (R *, R *)] - 2- (4-fluorophenyl) -, - dihydroxy-5- (1-methylethyl) -3-phenyl-4 - [(phenylamino) carbonyl] -1H- for the preparation of pyrrole-1-heptanoic acid and its pharmaceutically acceptable salts
HU208115B (en) 1989-10-03 1993-08-30 Biochemie Gmbh New process for producting pleuromutilin derivatives
FR2654935B1 (en) 1989-11-28 1994-07-01 Lvmh Rech USE OF XANTHINES, WHICH MAY BE INCORPORATED IN LIPOSOMES, TO PROMOTE PIGMENTATION OF THE SKIN OR HAIR.
DK0443983T3 (en) * 1990-02-19 1996-03-18 Ciba Geigy Ag acrylic Compounds
KR930000861B1 (en) 1990-02-27 1993-02-08 한미약품공업 주식회사 Omeprazole rectal composition
ATE112491T1 (en) 1990-09-13 1994-10-15 Akzo Nobel Nv STABILIZED SOLID CHEMICAL COMPOSITIONS.
GB9020959D0 (en) 1990-09-26 1990-11-07 Beecham Group Plc Novel compounds
US5084460A (en) * 1990-12-24 1992-01-28 A. H. Robins Company, Incorporated Methods of therapeutic treatment with N-(3-ouinuclidinyl)-2-hydroxybenzamides and thiobenzamides
US5602127A (en) 1991-02-06 1997-02-11 Karl Thomae Gmbh (Alkanesultam-1-yl)-benzimidazol-1-yl)-1yl)-methyl-biphenyls useful as angiotensin-II antagonists
US5594003A (en) 1991-02-06 1997-01-14 Dr. Karl Thomae Gmbh Tetrahydroimidazo[1,2-a]pyridin-2-yl-(benzimidazol-1-yl)-methyl-biphenyls useful as angiotensin-II antagonists
US5614519A (en) 1991-02-06 1997-03-25 Karl Thomae Gmbh (1-(2,3 or 4-N-morpholinoalkyl)-imidazol-4-yl)-benizimidazol-1-yl-methyl]-biphenyls useful as angiotensin-II antagonists
GB9109862D0 (en) 1991-05-08 1991-07-03 Beecham Lab Sa Pharmaceutical formulations
DE4124150A1 (en) * 1991-07-20 1993-01-21 Bayer Ag SUBSTITUTED TRIAZOLES
DE69233671T2 (en) 1991-10-22 2007-10-18 New England Medical Center Hospitals, Inc., Boston Inhibitors of dipeptidyl aminopeptidase type IV
US5300298A (en) * 1992-05-06 1994-04-05 The Pennsylvania Research Corporation Methods of treating obesity with purine related compounds
GB9215633D0 (en) 1992-07-23 1992-09-09 Smithkline Beecham Plc Novel treatment
EP0581552B1 (en) 1992-07-31 1998-04-22 Shionogi & Co., Ltd. Triazolylthiomethylthio cephalosporin hyrochloride, its crystalline hydrate and the production of the same
TW252044B (en) 1992-08-10 1995-07-21 Boehringer Ingelheim Kg
US5358941A (en) 1992-12-02 1994-10-25 Merck & Co., Inc. Dry mix formulation for bisphosphonic acids with lactose
DE4242459A1 (en) * 1992-12-16 1994-06-23 Merck Patent Gmbh imidazopyridines
AU6087894A (en) 1993-01-14 1994-08-15 Cell Therapeutics, Inc. Acetal or ketal substituted therapeutic compounds
EP0638567A4 (en) 1993-02-18 1995-05-10 Kyowa Hakko Kogyo Kk INHIBITOR OF ADENOSINE INCORPORATION.
JP3726291B2 (en) 1993-07-05 2005-12-14 三菱ウェルファーマ株式会社 Benzoxazine compound having stable crystal structure and process for producing the same
FR2707641B1 (en) 1993-07-16 1995-08-25 Fournier Ind & Sante Compounds of imidazol-5-carboxamide, their process for preparing their intermediates and their use in therapy.
DE4339868A1 (en) 1993-11-23 1995-05-24 Merck Patent Gmbh imidazopyridazines
DE4404183A1 (en) 1994-02-10 1995-08-17 Merck Patent Gmbh 4-amino-1-piperidylbenzoylguanidine
US5545745A (en) 1994-05-23 1996-08-13 Sepracor, Inc. Enantioselective preparation of optically pure albuterol
CO4410190A1 (en) 1994-09-19 1997-01-09 Lilly Co Eli 3- [4- (2-AMINOETOXI) -BENZOIL] -2-ARIL-6-HYDROXYBENZO [b] CRYSTALLINE THIOPHEN
PL319605A1 (en) 1994-10-12 1997-08-18 Euro Celtique Sa Novel benzoxazoles
GB9501178D0 (en) 1995-01-20 1995-03-08 Wellcome Found Guanine derivative
JPH11505241A (en) 1995-05-19 1999-05-18 カイロサイエンス・リミテッド Xanthines and their therapeutic use
JPH08333339A (en) 1995-06-08 1996-12-17 Fujisawa Pharmaceut Co Ltd Production of optically active piperidineacetic acid derivative
GB9523752D0 (en) 1995-11-21 1996-01-24 Pfizer Ltd Pharmaceutical formulations
DE19543478A1 (en) 1995-11-22 1997-05-28 Bayer Ag Crystalline hydrochloride of {(R) - (-) - 2N- [4- (1,1-dioxido-3-oxo-2,3-dihydrobenzisothiazol-2-yl) -buytl] aminomethyl} -chroman
FR2742751B1 (en) 1995-12-22 1998-01-30 Rhone Poulenc Rorer Sa NOVEL TAXOIDS, THEIR PREPARATION AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
EP0888293B1 (en) 1995-12-26 2002-03-27 Alteon, Inc. N-acylaminoalkylhydrazinecarboximidamides
US5891855A (en) 1996-02-12 1999-04-06 The Scripps Research Institute Inhibitors of leaderless protein export
DE19616486C5 (en) * 1996-04-25 2016-06-30 Royalty Pharma Collection Trust Method for lowering the blood glucose level in mammals
TWI240627B (en) 1996-04-26 2005-10-01 Chugai Pharmaceutical Co Ltd Erythropoietin solution preparation
WO1997046526A1 (en) 1996-06-07 1997-12-11 Eisai Co., Ltd. Stable polymorphs of donepezil (1-benzyl-4-[(5,6-dimethoxy-1-indanon)-2-yl]methylpiperidine) hydrochloride and process for production
US5965555A (en) 1996-06-07 1999-10-12 Hoechst Aktiengesellschaft Xanthine compounds having terminally animated alkynol side chains
US5958951A (en) 1996-06-14 1999-09-28 Novo Nordiskials Modified form of the R(-)-N-(4,4-di(3-methylthien-2-yl)but-3-enyl)-nipecotic acid hydrochloride
US5753635A (en) 1996-08-16 1998-05-19 Berlex Laboratories, Inc. Purine derivatives and their use as anti-coagulants
IL128956A0 (en) 1996-09-23 2000-02-17 Lilly Co Eli Olanzapine dihydrate D
EP0937056A1 (en) 1996-10-28 1999-08-25 Novo Nordisk A/S A process for the preparation of (-)-3,4-trans-diarylchromans
UA65549C2 (en) 1996-11-05 2004-04-15 Елі Ліллі Енд Компані Use of glucagon-like peptides such as glp-1, glp-1 analog, or glp-1 derivative in methods and compositions for reducing body weight
TW492957B (en) 1996-11-07 2002-07-01 Novartis Ag N-substituted 2-cyanopyrrolidnes
WO1998020895A1 (en) 1996-11-12 1998-05-22 Novo Nordisk A/S Use of glp-1 peptides
GB9623859D0 (en) 1996-11-15 1997-01-08 Chiroscience Ltd Novel compounds
KR101042660B1 (en) 1996-12-24 2011-06-20 바이오겐 아이덱 엠에이 인코포레이티드 Stable Liquid Interferon Formulations
DE19705233A1 (en) 1997-02-12 1998-08-13 Froelich Juergen C Preparation of stable, orally administered arginine solutions
US6011049A (en) 1997-02-19 2000-01-04 Warner-Lambert Company Combinations for diabetes
CN1113649C (en) 1997-03-13 2003-07-09 赫克萨尔股份公司 Stabilization of acid sensitive benzimidazoles with amino acid/cyclodextrin combinations
US5972332A (en) 1997-04-16 1999-10-26 The Regents Of The University Of Michigan Wound treatment with keratinocytes on a solid support enclosed in a porous material
PE79099A1 (en) 1997-06-13 1999-08-24 Lilly Co Eli STABLE INSULIN FORMULATIONS
CO4940418A1 (en) 1997-07-18 2000-07-24 Novartis Ag MODIFICATION OF A CRYSTAL OF A DERIVATIVE OF N-PHENYL-2-PIRIMIDINAMINE, PROCESSES FOR ITS MANUFACTURE AND USE
US6174548B1 (en) 1998-08-28 2001-01-16 Andrx Pharmaceuticals, Inc. Omeprazole formulation
NZ504452A (en) * 1997-12-05 2002-05-31 Astrazeneca Uk Ltd [3,4-d]Pyridazinones, process for their preparation and pharmaceutical compositions containing them
ID21411A (en) 1997-12-10 1999-06-10 Takeda Chemical Industries Ltd AGENTS TO TREAT GLUCOSE RESISTANCE THAT IS RISK OF HIGH DAMAGED
JPH11193270A (en) 1997-12-26 1999-07-21 Koei Chem Co Ltd Production of optically active 1-methyl-3-piperidinemethanol
EP1300147A1 (en) * 1998-01-05 2003-04-09 Eisai Co. Ltd Purine compounds and adenosine A2 receptor antagonist as preventive or therapeutic agent for diabetes mellitus
EP2583675A1 (en) 1998-02-02 2013-04-24 Trustees Of Tufts College Use of dipeptidylpeptidase inhibitors to regulate glucose metabolism
US20030013740A1 (en) 1998-03-27 2003-01-16 Martin P. Redmon Stable dosage forms of fluoxetine and its enantiomers
EP1066265A1 (en) 1998-03-31 2001-01-10 Nissan Chemical Industries, Ltd. Pyridazinone hydrochloride compound and method for producing the same
CA2268621A1 (en) 1998-04-13 1999-10-13 Takeda Chemical Industries, Ltd. 2-pipirazinone-1-acetic acid derivative, production and use thereof
US6207207B1 (en) 1998-05-01 2001-03-27 Mars, Incorporated Coated confectionery having a crispy starch based center and method of preparation
DE19823831A1 (en) * 1998-05-28 1999-12-02 Probiodrug Ges Fuer Arzneim New pharmaceutical use of isoleucyl thiazolidide and its salts
DE19828114A1 (en) 1998-06-24 2000-01-27 Probiodrug Ges Fuer Arzneim Produgs of unstable inhibitors of dipeptidyl peptidase IV
DE19828113A1 (en) 1998-06-24 2000-01-05 Probiodrug Ges Fuer Arzneim Prodrugs of Dipeptidyl Peptidase IV Inhibitors
WO2000003735A1 (en) 1998-07-15 2000-01-27 Asahi Kasei Kogyo Kabushiki Kaisha Excipient
GB9827133D0 (en) 1998-12-09 1999-02-03 Zeneca Ltd Chemical process
CO5150173A1 (en) 1998-12-10 2002-04-29 Novartis Ag COMPOUNDS N- (REPLACED GLYCLE) -2-DIPEPTIDYL-IV PEPTIDASE INHIBITING CYANOPIRROLIDINS (DPP-IV) WHICH ARE EFFECTIVE IN THE TREATMENT OF CONDITIONS MEDIATED BY DPP-IV INHIBITION
IT1312018B1 (en) 1999-03-19 2002-04-04 Fassi Aldo IMPROVED PROCEDURE FOR THE PRODUCTION OF NON HYGROSCOPICIDAL SALTS OF L (-) - CARNITINE.
WO2000066101A2 (en) 1999-04-30 2000-11-09 City Of Hope Method of inhibiting glycation product formation
US20040152659A1 (en) 1999-05-12 2004-08-05 Fujisawa Pharmaceutical Co. Ltd. Method for the treatment of parkinson's disease comprising administering an A1A2a receptor dual antagonist
EP1177797A1 (en) 1999-05-12 2002-02-06 Fujisawa Pharmaceutical Co., Ltd. Novel use
AU5294100A (en) 1999-05-27 2000-12-18 University Of Virginia Patent Foundation Method and compositions for treating the inflammatory response
WO2000072873A1 (en) 1999-05-31 2000-12-07 Mitsubishi Chemical Corporation Freeze dried hgf preparations
US6431478B1 (en) 1999-06-01 2002-08-13 Elan Pharma International Limited Small-scale mill and method thereof
US6545002B1 (en) 1999-06-01 2003-04-08 University Of Virginia Patent Foundation Substituted 8-phenylxanthines useful as antagonists of A2B adenosine receptors
HUP0201900A3 (en) * 1999-06-21 2003-02-28 Boehringer Ingelheim Pharma Bicyclic heterocycles, pharmaceutical compositions containing them, their use and methods for the production thereof
US6448323B1 (en) 1999-07-09 2002-09-10 Bpsi Holdings, Inc. Film coatings and film coating compositions based on polyvinyl alcohol
ES2166270B1 (en) 1999-07-27 2003-04-01 Almirall Prodesfarma Sa DERIVATIVES OF 8-PHENYL-6,9-DIHIDRO- (1,2,4,) TRIAZOLO (3,4-I) PURIN-5-ONA.
US6515117B2 (en) 1999-10-12 2003-02-04 Bristol-Myers Squibb Company C-aryl glucoside SGLT2 inhibitors and method
US6586438B2 (en) 1999-11-03 2003-07-01 Bristol-Myers Squibb Co. Antidiabetic formulation and method
GB9928330D0 (en) 1999-11-30 2000-01-26 Ferring Bv Novel antidiabetic agents
CN1911221A (en) 1999-12-23 2007-02-14 诺瓦提斯公司 Use of a hypoglycemic agent for treating impaired glucose metabolism
KR20020071931A (en) 2000-01-07 2002-09-13 트렌스폼 파마수티컬스 인코퍼레이티드 High-throughput formation, identification, and analysis of diverse solid-forms
US6362172B2 (en) 2000-01-20 2002-03-26 Bristol-Myers Squibb Company Water soluble prodrugs of azole compounds
PT1248604E (en) 2000-01-21 2007-01-31 Novartis Ag Combinations comprising dipeptidylpeptidase-iv inhibitors and antidiabetic agents
JP4621326B2 (en) * 2000-02-01 2011-01-26 エーザイ・アール・アンド・ディー・マネジメント株式会社 Teprenone stabilized composition
EP1196390A2 (en) * 2000-02-05 2002-04-17 Vertex Pharmaceuticals Incorporated Pyrazole compositions useful as inhibitors of erk
CA2401356A1 (en) 2000-02-24 2001-08-30 Takeda Chemical Industries, Ltd. Combination drug
EP1132389A1 (en) 2000-03-06 2001-09-12 Vernalis Research Limited New aza-indolyl derivatives for the treatment of obesity
US6395767B2 (en) 2000-03-10 2002-05-28 Bristol-Myers Squibb Company Cyclopropyl-fused pyrrolidine-based inhibitors of dipeptidyl peptidase IV and method
GB0006133D0 (en) 2000-03-14 2000-05-03 Smithkline Beecham Plc Novel pharmaceutical
JP2001278812A (en) * 2000-03-27 2001-10-10 Kyoto Pharmaceutical Industries Ltd Disintegrant for tablet and tablet using the same
US6399101B1 (en) 2000-03-30 2002-06-04 Mova Pharmaceutical Corp. Stable thyroid hormone preparations and method of making same
AU4458401A (en) 2000-03-31 2001-10-15 Kirin Brewery Powdery preparation for transmucosal administration containing a polymeric form of drug and exhibiting improved storage stability
CN101690815A (en) 2000-03-31 2010-04-07 普罗西迪恩有限公司 Novel use of dipeptidyl peptidase-iv inhibitor
JP2001292388A (en) 2000-04-05 2001-10-19 Sharp Corp Playback device
GB0008694D0 (en) 2000-04-07 2000-05-31 Novartis Ag Organic compounds
EP1295873A4 (en) 2000-06-14 2004-05-19 Processes for producing racemic piperidine derivative and for producing optically active piperidine derivative
GB0014969D0 (en) 2000-06-19 2000-08-09 Smithkline Beecham Plc Novel method of treatment
US7078397B2 (en) 2000-06-19 2006-07-18 Smithkline Beecham Corporation Combinations of dipeptidyl peptidase IV inhibitors and other antidiabetic agents for the treatment of diabetes mellitus
US6689353B1 (en) 2000-06-28 2004-02-10 Bayer Pharmaceuticals Corporation Stabilized interleukin 2
WO2002002560A2 (en) 2000-07-04 2002-01-10 Novo Nordisk A/S Purine-2,6-diones which are inhibitors of the enzyme dipeptidyl peptidase iv (dpp-iv)
PT1308439E (en) 2000-08-10 2008-12-12 Mitsubishi Tanabe Pharma Corp Proline derivatives and use thereof as drugs
US6821978B2 (en) 2000-09-19 2004-11-23 Schering Corporation Xanthine phosphodiesterase V inhibitors
US20060034922A1 (en) 2000-11-03 2006-02-16 Andrx Labs, Llc Controlled release metformin compositions
US6722883B2 (en) 2000-11-13 2004-04-20 G & H Technologies Llc Protective coating for abrasive dental tools and burs
US6821261B2 (en) 2000-12-12 2004-11-23 Dj Orthopedics, Llc Orthopedic brace having length-adjustable supports
JPWO2002051836A1 (en) 2000-12-27 2004-04-22 協和醗酵工業株式会社 Dipeptidyl peptidase-IV inhibitor
FR2818906B1 (en) 2000-12-29 2004-04-02 Dospharma DRUG ASSOCIATION OF A BIGUANINE AND A CARRIER, FOR EXAMPLE OF METFORMIN AND ARGININE
FR2819254B1 (en) 2001-01-08 2003-04-18 Fournier Lab Sa NOVEL N- (PHENYLSULFONYL) GLYCINE COMPOUNDS, PROCESS FOR THEIR PREPARATION AND THEIR USE FOR OBTAINING PHARMACEUTICAL COMPOSITIONS
DE10109021A1 (en) 2001-02-24 2002-09-05 Boehringer Ingelheim Pharma Xanthine derivatives, their production and their use as pharmaceuticals
DE10117803A1 (en) 2001-04-10 2002-10-24 Boehringer Ingelheim Pharma New 8-substituted-xanthine derivatives, useful e.g. for treating diabetes and arthritis, act by inhibiting dipeptidylpeptidase-IV
PL364221A1 (en) 2001-02-02 2004-12-13 Takeda Chemical Industries, Ltd. Fused heterocyclic compounds
US6649187B2 (en) 2001-02-16 2003-11-18 Bristol-Myers Squibb Pharma Company Use of polyalkylamine polymers in controlled release devices
US6610326B2 (en) 2001-02-16 2003-08-26 Andrx Corporation Divalproex sodium tablets
RS55023B1 (en) 2001-02-24 2016-11-30 Boehringer Ingelheim Pharma Xantine derivatives, production and use thereof as a medicament
US6936590B2 (en) 2001-03-13 2005-08-30 Bristol Myers Squibb Company C-aryl glucoside SGLT2 inhibitors and method
US6693094B2 (en) 2001-03-22 2004-02-17 Chrono Rx Llc Biguanide and sulfonylurea formulations for the prevention and treatment of insulin resistance and type 2 diabetes mellitus
JP2002348279A (en) 2001-05-25 2002-12-04 Nippon Kayaku Co Ltd Production method for optically active pyridylketone derivatives and optically active pyridylketone derivatives
DE10130371A1 (en) 2001-06-23 2003-01-02 Boehringer Ingelheim Pharma New drug compositions based on anticholinergics, corticosteroids and betamimetics
GB0115517D0 (en) 2001-06-25 2001-08-15 Ferring Bv Novel antidiabetic agents
ATE370943T1 (en) 2001-06-27 2007-09-15 Smithkline Beecham Corp FLUOROPYRROLIDINE AS DIPEPTIDYL-PEPTIDASE INHIBITORS
WO2003002531A2 (en) 2001-06-27 2003-01-09 Smithkline Beecham Corporation Fluoropyrrolidines as dipeptidyl peptidase inhibitors
US6869947B2 (en) * 2001-07-03 2005-03-22 Novo Nordisk A/S Heterocyclic compounds that are inhibitors of the enzyme DPP-IV
EP1404675B1 (en) 2001-07-03 2008-03-12 Novo Nordisk A/S Dpp-iv-inhibiting purine derivatives for the treatment of diabetes
UA74912C2 (en) 2001-07-06 2006-02-15 Merck & Co Inc Beta-aminotetrahydroimidazo-(1,2-a)-pyrazines and tetratriazolo-(4,3-a)-pyrazines as inhibitors of dipeptylpeptidase for the treatment or prevention of diabetes
WO2003006424A1 (en) 2001-07-10 2003-01-23 4Sc Ag Novel compounds as anti-inflammatory, immunomodulatory and anti-proliferatory agents
US7085258B2 (en) * 2001-07-19 2006-08-01 International Business Machines Corporation Instant messaging with voice conversation feature
US6955933B2 (en) 2001-07-24 2005-10-18 Lumileds Lighting U.S., Llc Light emitting diodes with graded composition active regions
US7638522B2 (en) 2001-08-13 2009-12-29 Janssen Pharmaceutica N.V. Salt of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino] benzonitrile
AR035119A1 (en) 2001-08-16 2004-04-14 Lilly Co Eli ANTI-HTNFSF13B HUMAN ANTI-BODIES
JPWO2003024942A1 (en) 2001-09-14 2004-12-24 三菱ウェルファーマ株式会社 Thiazolidine derivatives and their pharmaceutical uses
EP1463727A2 (en) * 2001-09-19 2004-10-06 Novo Nordisk A/S Heterocyclic compounds that are inhibitors of the enzyme dpp-iv
JP2005514008A (en) 2001-09-24 2005-05-19 オレゴン ヘルス アンド サイエンス ユニバーシティー Methods for evaluating neurons in the arcuate nucleus to screen for drugs that alter feeding behavior
DK1435877T3 (en) 2001-10-15 2009-08-03 Hemoteq Ag Coating of stents to prevent restenosis
DE10151296A1 (en) 2001-10-17 2003-04-30 Boehringer Ingelheim Pharma Keratinocytes useful as a biologically active substance in the treatment of wounds
US6723340B2 (en) 2001-10-25 2004-04-20 Depomed, Inc. Optimal polymer mixtures for gastric retentive tablets
US20030083354A1 (en) 2001-10-26 2003-05-01 Pediamed Pharmaceuticals, Inc. Phenylephrine tannate and pyrilamine tannate salts in pharmaceutical compositions
US6861440B2 (en) 2001-10-26 2005-03-01 Hoffmann-La Roche Inc. DPP IV inhibitors
BR0213958A (en) 2001-10-31 2004-09-08 Novartis Ag Methods for treating diabetes and related conditions based on tcf1 gene polymorphisms
CA2363053C (en) 2001-11-09 2011-01-25 Bernard Charles Sherman Clopidogrel bisulfate tablet formulation
WO2003045228A2 (en) 2001-11-26 2003-06-05 Trustees Of Tufts College Methods for treating autoimmune disorders, and reagents related thereto
KR20040064687A (en) 2001-12-21 2004-07-19 도오레 화인케미칼 가부시키가이샤 Process for production of optically active cis-piperidine derivatives
US6727261B2 (en) 2001-12-27 2004-04-27 Hoffman-La Roche Inc. Pyrido[2,1-A]Isoquinoline derivatives
CA2471766C (en) 2001-12-28 2011-01-11 Nrl Pharma, Inc. Compositions for improving lipid metabolism
AU2003201998C1 (en) 2002-01-10 2012-10-25 Imperial Innovations Limited Modification of feeding behavior
ATE409466T1 (en) 2002-01-11 2008-10-15 Novo Nordisk As METHOD AND COMPOSITION FOR TREATING DIABETES, HYPERTENSION, CHRONIC HEART FAILURE AND CONDITIONS ASSOCIATED WITH FLUID RETENTION
US20070197552A1 (en) 2002-01-11 2007-08-23 Novo Nordisk A/S Method and composition for treatment of diabetes, hypertension, chronic heart failure and fluid retentive states
CN100571695C (en) 2002-01-16 2009-12-23 贝林格尔英格海姆法玛两合公司 Double-layer tablet containing telmisartan and diuretic and preparation method thereof
EP1477182A4 (en) 2002-01-21 2009-05-27 Nrl Pharma Inc Novel analgesics
EP1333033A1 (en) 2002-01-30 2003-08-06 Boehringer Ingelheim Pharma GmbH & Co.KG FAP-activated anti-tumor compounds
JP2005517690A (en) * 2002-02-01 2005-06-16 ファイザー・プロダクツ・インク Immediate release dosage form containing solid drug dispersion
US7610153B2 (en) 2002-02-13 2009-10-27 Virginia Commonwealth University Multi-drug titration and evaluation
EP1476139B1 (en) 2002-02-21 2017-05-17 Valeant Pharmaceuticals Luxembourg S.à.r.l. Controlled release dosage forms
US7074798B2 (en) * 2002-02-25 2006-07-11 Eisai Co., Ltd Xanthine derivative and DPPIV inhibitor
HUP0200849A2 (en) 2002-03-06 2004-08-30 Sanofi-Synthelabo N-aminoacetyl-pyrrolidine-2-carbonitrile derivatives, pharmaceutical compositions containing them and process for producing them
JP4298212B2 (en) 2002-03-29 2009-07-15 大日本印刷株式会社 Method for producing high melting point type epinastine hydrochloride
JP2003300977A (en) 2002-04-10 2003-10-21 Sumitomo Pharmaceut Co Ltd Xanthine derivative
JP2005528400A (en) 2002-04-16 2005-09-22 メルク　エンド　カムパニー　インコーポレーテッド Solid form of salt with tyrosine kinase activity
AU2003231517A1 (en) 2002-04-26 2003-11-10 Ajinomoto Co., Inc. Preventive/remedy for diabetes
WO2003094909A2 (en) 2002-05-09 2003-11-20 Enos Pharmaceuticals, Inc. Methods and compositions for the treatment and prevention of intermittent claudication or alzheimer's disease
GB0212412D0 (en) 2002-05-29 2002-07-10 Novartis Ag Combination of organic compounds
ES2270047T3 (en) 2002-05-31 2007-04-01 Schering Corporation PROCESS TO PREPARE INHIBITORS OF THE PHANTOSPHODESTERASE V OF XANTINA AND ITS PRECURSORS.
RU2297418C9 (en) 2002-06-06 2009-01-27 Эйсай Ко., Лтд. Novel condensed derivatives of imidazole, inhibitors of dipeptidyl peptidase iv, pharmaceutical composition, method of treatment and using based on thereof
ES2199061B1 (en) * 2002-06-10 2005-02-16 Laboratorios Vita, S.A. TROUBLE-BASED TABLETS AND PROCEDURE FOR OBTAINING.
FR2840897B1 (en) 2002-06-14 2004-09-10 Fournier Lab Sa NOVEL ARYLSULFONAMIDE DERIVATIVES AND THEIR USE IN THERAPEUTICS
US20040002615A1 (en) 2002-06-28 2004-01-01 Allen David Robert Preparation of chiral amino-nitriles
US7065367B2 (en) * 2002-07-11 2006-06-20 Oliver Michaelis Interface selection in a wireless communication network
US20040023981A1 (en) 2002-07-24 2004-02-05 Yu Ren Salt forms with tyrosine kinase activity
TW200409746A (en) 2002-07-26 2004-06-16 Theravance Inc Crystalline β2 adrenergic receptor agonist
ITMI20021725A1 (en) 2002-08-01 2002-10-31 Zambon Spa PHARMACEUTICAL COMPOSITIONS WITH ANTIBIOTIC ACTIVITY.
TW200404796A (en) 2002-08-19 2004-04-01 Ono Pharmaceutical Co Nitrogen-containing compound
US7407955B2 (en) 2002-08-21 2008-08-05 Boehringer Ingelheim Pharma Gmbh & Co., Kg 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
DE10238243A1 (en) 2002-08-21 2004-03-04 Boehringer Ingelheim Pharma Gmbh & Co. Kg New 8-(3-amino-piperidin-1-yl)-xanthine derivatives are dipeptidylpeptidase-IV inhibitors useful for, e.g. treating diabetes mellitus, arthritis or obesity
BRPI0313648B8 (en) 2002-08-21 2021-05-25 Boehringer Ingelheim Pharma 8-[3-amino-piperidin-1-yl]-xanthines, their physiologically compatible salts, their uses and their preparation processes, as well as medicines containing them and their preparation processes
US7569574B2 (en) * 2002-08-22 2009-08-04 Boehringer Ingelheim Pharma Gmbh & Co. Kg Purine derivatives, the preparation thereof and their use as pharmaceutical compositions
US7495005B2 (en) 2002-08-22 2009-02-24 Boehringer Ingelheim Pharma Gmbh & Co. Kg Xanthine derivatives, their preparation and their use in pharmaceutical compositions
DE10238477A1 (en) 2002-08-22 2004-03-04 Boehringer Ingelheim Pharma Gmbh & Co. Kg New purine derivatives, their production and their use as medicines
DE10238470A1 (en) 2002-08-22 2004-03-04 Boehringer Ingelheim Pharma Gmbh & Co. Kg New xanthine derivatives, their production and their use as medicines
DE10238724A1 (en) 2002-08-23 2004-03-04 Bayer Ag New 6-alkyl-1,5-dihydro-4H-pyrazolo-(3,4-d)-pyrimidin-4-ones useful as selective phosphodiesterase 9A inhibitors for improving attention, concentration, learning and/or memory performance
DE10238723A1 (en) 2002-08-23 2004-03-11 Bayer Ag Phenyl substituted pyrazolyprimidines
JP2004123738A (en) * 2002-09-11 2004-04-22 Takeda Chem Ind Ltd Sustained-release preparation
AU2003262059A1 (en) * 2002-09-11 2004-04-30 Takeda Pharmaceutical Company Limited Sustained release preparation
US20040126358A1 (en) * 2002-09-16 2004-07-01 Warne Nicholas W. Delayed release formulations for oral administration of a polypeptide therapeutic agent and methods of using same
US7262207B2 (en) 2002-09-19 2007-08-28 Abbott Laboratories Pharmaceutical compositions as inhibitors of dipeptidyl peptidase-IV (DPP-IV)
RU2328280C2 (en) 2002-09-26 2008-07-10 Эйсай Ар Энд Ди Менеджмент Ко., Лтд. Combinative medicinal agent
AU2003269850A1 (en) 2002-10-08 2004-05-04 Novo Nordisk A/S Hemisuccinate salts of heterocyclic dpp-iv inhibitors
EP1558218A1 (en) * 2002-10-08 2005-08-03 Ranbaxy Laboratories Limited Gabapentin tablets and methods for their preparation
US20040122048A1 (en) 2002-10-11 2004-06-24 Wyeth Holdings Corporation Stabilized pharmaceutical composition containing basic excipients
US6861526B2 (en) 2002-10-16 2005-03-01 Pfizer Inc. Process for the preparation of (S,S)-cis-2-benzhydryl-3-benzylaminoquinuclidine
WO2004037169A2 (en) 2002-10-18 2004-05-06 Merck & Co., Inc. Beta-amino heterocyclic dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes
JP2004161749A (en) 2002-10-24 2004-06-10 Toray Fine Chemicals Co Ltd Method for producing optically active, nitrogen-containing compound
AU2003280680A1 (en) 2002-11-01 2004-06-18 Sumitomo Pharmaceuticals Co., Ltd. Xanthine compound
BR0315796A (en) 2002-11-07 2005-09-13 Merck & Co Inc Compound, Pharmaceutical Composition, and, Methods for Treating Diabetes, Treating Hyperglycemia, and Treating Obesity in a Mammal
US7482337B2 (en) * 2002-11-08 2009-01-27 Boehringer Ingelheim Pharma Gmbh & Co. Kg Xanthine derivatives, the preparation thereof and their use as pharmaceutical compositions
DE10251927A1 (en) 2002-11-08 2004-05-19 Boehringer Ingelheim Pharma Gmbh & Co. Kg New 1,7,8-trisubstituted xanthine derivatives, are dipeptidylpeptidase-IV inhibitors useful e.g. for treating diabetes mellitus type I or II, arthritis or obesity
DE10254304A1 (en) * 2002-11-21 2004-06-03 Boehringer Ingelheim Pharma Gmbh & Co. Kg New xanthine derivatives, their production and their use as medicines
US7109192B2 (en) * 2002-12-03 2006-09-19 Boehringer Ingelheim Pharma Gmbh & Co Kg Substituted imidazo-pyridinones and imidazo-pyridazinones, the preparation thereof and their use as pharmaceutical compositions
UY28103A1 (en) 2002-12-03 2004-06-30 Boehringer Ingelheim Pharma NEW IMIDAZO-PIRIDINONAS REPLACED, ITS PREPARATION AND ITS EMPLOYMENT AS MEDICATIONS
CA2505771A1 (en) 2002-12-10 2004-06-24 Novartis Ag Combination of an dpp-iv inhibitor and a ppar-alpha compound
UA83813C2 (en) 2002-12-20 2008-08-26 Бёрингер Ингельхайм Фарма Гмбх & Ко. Кг Powdered medicament for inhalation comprising a tiotropium salt and salmeterol xinafoate
US20040152720A1 (en) 2002-12-20 2004-08-05 Boehringer Ingelheim Pharma Gmbh & Co. Kg Powdered medicaments containing a tiotropium salt and salmeterol xinafoate
EP1599222B1 (en) 2003-01-08 2009-03-04 Novartis Vaccines and Diagnostics, Inc. Stabilized aqueous compositions comprising tissue factor pathway inhibitor (tfpi) or tissue factor pathway inhibitor variant
ES2295816T3 (en) 2003-01-14 2008-04-16 Arena Pharmaceuticals, Inc. ARILO AND HETEROARILO 1,2,3-TRISUSTITUTED DERIVATIVES AS METABOLISM MODULATORS, AND PROFILAXIS AND TREATMENT OF DISORDERS RELATED TO THE SAME, SUCH AS DIABETES AND HYPERGLUCEMIA.
DE10335027A1 (en) 2003-07-31 2005-02-17 Boehringer Ingelheim Pharma Gmbh & Co. Kg Use of telmisartan and simvastatin for treatment or prophylaxis of cardiovascular, cardiopulmonary and renal diseases e.g. hypertension combined with hyperlipidemia or atherosclerosis
PE20040950A1 (en) 2003-02-14 2005-01-01 Theravance Inc BIPHENYL DERIVATIVES AS AGONISTS OF ß2-ADRENERGIC RECEPTORS AND AS ANTAGONISTS OF MUSCARINAL RECEPTORS
JP2004250336A (en) * 2003-02-18 2004-09-09 Kao Corp Process for producing coated tablets and sugar-coated tablets
US7135575B2 (en) 2003-03-03 2006-11-14 Array Biopharma, Inc. P38 inhibitors and methods of use thereof
US7442387B2 (en) 2003-03-06 2008-10-28 Astellas Pharma Inc. Pharmaceutical composition for controlled release of active substances and manufacturing method thereof
EP1606290A1 (en) 2003-03-12 2005-12-21 Arizona Board of Regents, acting on behalf of the University of Arizona Weak base salts
JP2006520335A (en) 2003-03-18 2006-09-07 ノバルティス アクチエンゲゼルシャフト Compositions containing fatty acids and amino acids
HRP20150037T4 (en) 2003-04-08 2022-09-02 Progenics Pharmaceuticals, Inc. PHARMACEUTICAL FORMULATIONS CONTAINING METHYLNALTREXONE
US20040220186A1 (en) 2003-04-30 2004-11-04 Pfizer Inc. PDE9 inhibitors for treating type 2 diabetes,metabolic syndrome, and cardiovascular disease
JPWO2004096806A1 (en) 2003-04-30 2006-07-13 大日本住友製薬株式会社 Condensed imidazole derivatives
EP1631680A2 (en) 2003-05-21 2006-03-08 Bayer HealthCare AG Diagnostics and therapeutics for diseases associated with dipeptidylpeptidase iv (dpp4)
TW200510277A (en) 2003-05-27 2005-03-16 Theravance Inc Crystalline form of β2-adrenergic receptor agonist
FR2855521B1 (en) 2003-05-28 2005-08-05 Flamel Tech Sa POLYAMINOACIDES FUNCTIONALIZED BY AT LEAST ONE YDROPHOBIC GROUP AND THEIR PARTICULARLY THERAPEUTIC APPLICATIONS.
AU2003902828A0 (en) 2003-06-05 2003-06-26 Fujisawa Pharmaceutical Co., Ltd. Dpp-iv inhibitor
JP4210558B2 (en) 2003-06-17 2009-01-21 三菱電機株式会社 Planar light source device and display device using the same
US7566707B2 (en) * 2003-06-18 2009-07-28 Boehringer Ingelheim International Gmbh Imidazopyridazinone and imidazopyridone derivatives, the preparation thereof and their use as pharmaceutical compositions
DE10327439A1 (en) 2003-06-18 2005-01-05 Boehringer Ingelheim Pharma Gmbh & Co. Kg Novel imidazopyridazinone and imidazopyridone derivatives, their production and their use as pharmaceuticals
ATE437876T1 (en) 2003-06-20 2009-08-15 Hoffmann La Roche HEXAHYDROPYRIDOISOCHINOLINES AS DPP-IV INHIBITORS
ATE489387T1 (en) 2003-06-20 2010-12-15 Hoffmann La Roche PYRIDOÄ2,1-AÜ-ISOCHINOLINE DERIVATIVES AS DPP-IV INHIBITORS
JO2625B1 (en) * 2003-06-24 2011-11-01 ميرك شارب اند دوم كوربوريشن Phosphoric acid salt of a dipeptidyl peptidase-IV inhibitor
US7364755B2 (en) 2003-07-07 2008-04-29 Synthon Ip Inc. Modified calcium phosphate excipient
AR045047A1 (en) 2003-07-11 2005-10-12 Arena Pharm Inc ARILO AND HETEROARILO DERIVATIVES TRISUSTITUIDOS AS MODULATORS OF METABOLISM AND PROFILAXIS AND TREATMENT OF DISORDERS RELATED TO THEMSELVES
JP4920410B2 (en) 2003-07-14 2012-04-18 アリーナ ファーマシューティカルズ， インコーポレイテッド Fused aryl and heteroaryl derivatives as metabolic modulators and prevention and treatment of metabolic-related disorders
US20050027012A1 (en) 2003-07-16 2005-02-03 Boehringer Ingelheim International Gmbh Tablets containing ambroxol
PT1558220E (en) 2003-07-24 2010-03-12 Rasendrakumar Jha Oral compositions for treatment of diabetes
WO2005012288A1 (en) * 2003-08-01 2005-02-10 Genelabs Technologies, Inc Bicyclic imidazol derivatives against flaviviridae
US6995183B2 (en) 2003-08-01 2006-02-07 Bristol Myers Squibb Company Adamantylglycine-based inhibitors of dipeptidyl peptidase IV and methods
CA2534028A1 (en) 2003-08-14 2005-02-24 Novo Nordisk Health Care Ag Liquid, aqueous pharmaceutical composition of factor vii polypeptides
EP2226072A1 (en) * 2003-08-29 2010-09-08 Aton Pharma, Inc. Combinations of suberoylanilide hydroxamic acid and antimetbolic agents for treating cancer
US7790734B2 (en) 2003-09-08 2010-09-07 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
CA2540741A1 (en) 2003-10-03 2005-04-14 Takeda Pharmaceutical Company Limited Agent for treating diabetes
BR0304443B1 (en) 2003-10-28 2012-08-21 process for obtaining high thio2 and low radionuclide titanium concentrates from mechanical anatase concentrates.
US7107714B2 (en) 2003-11-10 2006-09-19 Marketing Displays, Inc. Portable snap-fit sign stand
CA2545641A1 (en) 2003-11-17 2005-06-02 Novartis Ag Use of organic compounds
DE10355304A1 (en) 2003-11-27 2005-06-23 Boehringer Ingelheim Pharma Gmbh & Co. Kg Novel 8- (piperazin-1-yl) and 8 - ([1,4] diazepan-1-yl) xanthines, their preparation and their use as pharmaceuticals
JPWO2005053695A1 (en) * 2003-12-04 2007-12-06 エーザイ・アール・アンド・ディー・マネジメント株式会社 Agents for preventing or treating multiple sclerosis
US7217711B2 (en) * 2003-12-17 2007-05-15 Boehringer Ingelheim International Gmbh Piperazin-1-yl and 2-([1,4]diazepan-1-yl)-imidazo[4,5-d]-pyridazin-4-ones, the preparation thereof and their use as pharmaceutical compositions
DE10359098A1 (en) 2003-12-17 2005-07-28 Boehringer Ingelheim Pharma Gmbh & Co. Kg Novel 2- (piperazin-1-yl) and 2 - ([1,4] diazepan-1-yl) imidazo [4,5-d] pyridazin-4-ones, their preparation and their use as pharmaceuticals
ATE501135T1 (en) * 2003-12-18 2011-03-15 Tibotec Pharm Ltd PIPERIDINAMINO-BENZIMIDAZOLE DERIVATIVES AL RESPIRATORY SYNCYTIALVIRUS REPLICATION INHIBITORS
DE10360835A1 (en) * 2003-12-23 2005-07-21 Boehringer Ingelheim Pharma Gmbh & Co. Kg New bicyclic imidazole derivatives are dipeptidylpeptidase-IV inhibitors useful to treat e.g. arthritis, obesity, allograft transplantation and calcitonin-induced osteoporosis
NZ547965A (en) 2003-12-24 2009-12-24 Prosidion Ltd 1,2,4-Oxadiazole derivatives as GPCR receptor agonists
WO2005070390A2 (en) 2004-01-21 2005-08-04 Janssen Pharmaceutica N.V. Mitratapide oral solution
SE0400234D0 (en) 2004-02-06 2004-02-06 Active Biotech Ab New compounds, methods for their preparation and use thereof
EP1758905B1 (en) 2004-02-18 2009-04-29 Boehringer Ingelheim International GmbH 8-[3-amino-piperidin-1-yl]-xanthine, the production thereof and the use in the form of a ddp-iv inhibitor
US7501426B2 (en) * 2004-02-18 2009-03-10 Boehringer Ingelheim International Gmbh 8-[3-amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical compositions
DE102004019540A1 (en) 2004-04-22 2005-11-10 Boehringer Ingelheim Pharma Gmbh & Co. Kg Composition, useful for treatment of e.g. inflammatory and obstructive respiratory complaint, sinus rhythm in heart in atrioventricular block and circulatory shock, comprises 6-hydroxy-4H-benzo1,4oxazin-3-one derivatives and other actives
DE102004009039A1 (en) * 2004-02-23 2005-09-08 Boehringer Ingelheim Pharma Gmbh & Co. Kg 8- [3-Amino-piperidin-1-yl] xanthines, their preparation and use as pharmaceuticals
EP1593671A1 (en) 2004-03-05 2005-11-09 Graffinity Pharmaceuticals AG DPP-IV inhibitors
US7393847B2 (en) * 2004-03-13 2008-07-01 Boehringer Ingleheim International Gmbh Imidazopyridazinediones, their preparation and their use as pharmaceutical compositions
WO2005095381A1 (en) 2004-03-15 2005-10-13 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
WO2005092877A1 (en) 2004-03-16 2005-10-06 Boehringer Ingelheim International Gmbh Glucopyranosyl-substituted benzol derivatives, drugs containing said compounds, the use thereof and method for the production thereof
EP1577306A1 (en) 2004-03-17 2005-09-21 Boehringer Ingelheim Pharma GmbH & Co.KG novel benzoxazinone derivatives as slow-acting betamimetics and use thereof in treatment of respiratory tract diseases
WO2005097798A1 (en) 2004-04-10 2005-10-20 Boehringer Ingelheim International Gmbh Novel 2-amino-imidazo[4,5-d]pyridazin-4-ones and 2-amino-imidazo[4,5-c]pyridin-4-ones, production and use thereof as medicaments
US7179809B2 (en) * 2004-04-10 2007-02-20 Boehringer Ingelheim International Gmbh 2-Amino-imidazo[4,5-d]pyridazin-4-ones, their preparation and their use as pharmaceutical compositions
US20050239778A1 (en) 2004-04-22 2005-10-27 Boehringer Ingelheim International Gmbh Novel medicament combinations for the treatment of respiratory diseases
US20050244502A1 (en) 2004-04-28 2005-11-03 Mathias Neil R Composition for enhancing absorption of a drug and method
JP4976281B2 (en) 2004-05-03 2012-07-18 オメガ バイオ‐ファーマ（アイ．ピー．３）リミテッド Materials and methods for regulating metabolism
US7439370B2 (en) 2004-05-10 2008-10-21 Boehringer Ingelheim International Gmbh Imidazole derivatives, their preparation and their use as intermediates for the preparation of pharmaceutical compositions and pesticides
DE602005015699D1 (en) 2004-05-12 2009-09-10 Pfizer Prod Inc PROLIN DERIVATIVES AND THEIR USE AS DIPEPTIDYLPEPTIDASE IV INHIBITORS
DE102004024454A1 (en) 2004-05-14 2005-12-08 Boehringer Ingelheim Pharma Gmbh & Co. Kg Novel enantiomerically pure beta agonists, process for their preparation and their use as pharmaceuticals
PE20060315A1 (en) 2004-05-24 2006-05-15 Irm Llc THIAZOLE COMPOUNDS AS PPAR MODULATORS
TWI415635B (en) 2004-05-28 2013-11-21 必治妥施貴寶公司 Coated tablet formulation and method
BRPI0510527A (en) 2004-06-01 2007-10-30 Ares Trading Sa protein stabilization method
MXPA06014083A (en) 2004-06-03 2007-02-15 Pfizer Prod Inc Crystal structure of dipeptidyl peptidase iv (dpp-iv) and uses thereof.
US7935723B2 (en) 2004-06-04 2011-05-03 Novartis Pharma Ag Use of organic compounds
EP1604989A1 (en) 2004-06-08 2005-12-14 Santhera Pharmaceuticals (Deutschland) Aktiengesellschaft DPP-IV inhibitors
EP1753459A2 (en) 2004-06-09 2007-02-21 Yasoo Health Composition and method for improving pancreatic islet cell survival
DE102004030502A1 (en) * 2004-06-24 2006-01-12 Boehringer Ingelheim Pharma Gmbh & Co. Kg Novel imidazoles and triazoles, their preparation and use as medicines
CA2511269A1 (en) 2004-07-07 2006-01-07 F. Hoffmann-La Roche Ag Multimarker panel based on p1gf for diabetes type 1 and 2
WO2006005613A1 (en) 2004-07-14 2006-01-19 Novartis Ag Combination of dpp-iv inhibitors and compounds modulating 5-ht3 and/or 5-ht4 receptors
JP2006045156A (en) 2004-08-06 2006-02-16 Sumitomo Pharmaceut Co Ltd Condensed pyrazole derivatives
TW200613275A (en) 2004-08-24 2006-05-01 Recordati Ireland Ltd Lercanidipine salts
JP4854511B2 (en) 2004-08-26 2012-01-18 武田薬品工業株式会社 Diabetes treatment
DE102004043944A1 (en) * 2004-09-11 2006-03-30 Boehringer Ingelheim Pharma Gmbh & Co. Kg Novel 8- (3-amino-piperidin-1-yl) -7- (but-2-ynyl) -xanthines, their preparation and their use as pharmaceuticals
DE102004044221A1 (en) 2004-09-14 2006-03-16 Boehringer Ingelheim Pharma Gmbh & Co. Kg New 3-methyl-7-butynyl xanthines, their preparation and their use as pharmaceuticals
CN1759834B (en) 2004-09-17 2010-06-23 中国医学科学院医药生物技术研究所 Application of berberine or associated with Simvastatin in preparing product for preventing or curing disease or symptom related to blood fat
CA2580461A1 (en) 2004-09-23 2006-04-06 Amgen Inc. Substituted sulfonamidopropionamides and methods of use
EP1802308A1 (en) 2004-10-08 2007-07-04 Novartis AG Combination of organic compounds
NZ554515A (en) 2004-10-12 2009-12-24 Glenmark Pharmaceuticals Sa Novel dipeptidyl peptidase IV inhibitors, pharmaceutical compositions containing them, and process for their preparation
MX2007004934A (en) 2004-10-25 2007-06-12 Novartis Ag Combination of dpp-iv inhibitor, ppar antidiabetic and metformin.
DE102005013967A1 (en) 2004-11-05 2006-10-05 Boehringer Ingelheim Pharma Gmbh & Co. Kg New imidazole or pyrimidine derivatives are bradykinin B1 antagonists used for treating e.g. pain, stroke, peptic ulcers and other inflammatory disorders
DE102004054054A1 (en) 2004-11-05 2006-05-11 Boehringer Ingelheim Pharma Gmbh & Co. Kg Process for preparing chiral 8- (3-amino-piperidin-1-yl) -xanthines
JP2006137678A (en) 2004-11-10 2006-06-01 Shionogi & Co Ltd Interleukin-2 composition
EP1829877A4 (en) 2004-12-24 2009-10-14 Dainippon Sumitomo Pharma Co Bicyclic pyrrole derivatives
KR100760430B1 (en) 2004-12-31 2007-10-04 한미약품 주식회사 Sustained release combination preparations for oral administration of a diabetes treatment and preparation method thereof
MY148521A (en) 2005-01-10 2013-04-30 Arena Pharm Inc Substituted pyridinyl and pyrimidinyl derivatives as modulators of metabolism and the treatment of disorders related thereto
DOP2006000008A (en) 2005-01-10 2006-08-31 Arena Pharm Inc COMBINED THERAPY FOR THE TREATMENT OF DIABETES AND RELATED AFFECTIONS AND FOR THE TREATMENT OF AFFECTIONS THAT IMPROVE THROUGH AN INCREASE IN THE BLOOD CONCENTRATION OF GLP-1
GT200600008A (en) 2005-01-18 2006-08-09 FORMULATION OF DIRECT COMPRESSION AND PROCESS
WO2006111169A1 (en) 2005-04-21 2006-10-26 Gastrotech Pharma A/S Pharmaceutical preparations of a glp-1 molecule and an anti-emetic drug
WO2006116157A2 (en) 2005-04-22 2006-11-02 Alantos Pharmaceuticals Holding, Inc. Dipeptidyl peptidase-iv inhibitors
UA91546C2 (en) 2005-05-03 2010-08-10 Бьорінгер Інгельхайм Інтернаціональ Гмбх Crystalline form of 1-chloro-4-(я-d-glucopyranos-1-yl)-2-[4-((s)-tetrahydrofuran-3-yloxy)-benzyl]-benzene, a method for its preparation and the use thereof for preparing medicaments
RU2007143161A (en) 2005-05-25 2009-07-10 Вайет (Us) METHODS FOR SYNTHESIS OF SUBSTITUTED 3-CYANOCHINES AND THEIR PRODUCTS
CA2610361C (en) 2005-06-03 2013-11-26 Mitsubishi Tanabe Pharma Corporation Combination of 3-{(2s,4s)-4-[4-(3-methyl-1-phenyl-1h-pyrazol-5-yl)piperazin-1-yl]pyrrolidin-2-ylcarbonyl}thiazolidine and a second active agent and use thereof for plasma glucose control
GT200600218A (en) 2005-06-10 2007-03-28 FORMULATION AND PROCESS OF DIRECT COMPRESSION
AU2006260477B2 (en) 2005-06-20 2012-02-23 Decode Genetics Ehf. Genetic variants in the TCF7L2 gene as diagnostic markers for risk of type 2 diabetes mellitus
ES2351057T3 (en) 2005-07-08 2011-01-31 Pfizer Limited ANTIBODIES AGAINST MADCAM.
US20070014855A1 (en) 2005-07-12 2007-01-18 Rahul Gawande S Stable desloratadine compositions
UY29694A1 (en) 2005-07-28 2007-02-28 Boehringer Ingelheim Int METHODS TO PREVENT AND TREAT METABOLIC AND NEW DISORDERS DERIVED FROM PIRAZOL-O-GLUCOSIDO
DE102005035891A1 (en) * 2005-07-30 2007-02-08 Boehringer Ingelheim Pharma Gmbh & Co. Kg 8- (3-amino-piperidin-1-yl) -xanthines, their preparation and their use as pharmaceuticals
BRPI0614732A2 (en) * 2005-08-11 2011-04-12 Hoffmann La Roche A pharmaceutical composition comprising a dpp-iv inhibitor, use of a dpp-iv inhibitor and method for treating diseases associated with high blood glucose levels.
EP1760076A1 (en) 2005-09-02 2007-03-07 Ferring B.V. FAP Inhibitors
CA2622472C (en) 2005-09-14 2013-11-19 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors for treating diabetes
BRPI0616077B8 (en) 2005-09-14 2021-05-25 Takeda Pharmaceuticals Co pharmaceutical composition formulated in a single dose, kit, article of manufacture, use of the pharmaceutical composition and use of one or more antidiabetic compounds
ES2326391T3 (en) 2005-09-16 2009-10-08 Arena Pharmaceuticals, Inc. METABOLISM MODULATORS AND THE TREATMENT OF DISORDERS RELATED TO THE SAME.
KR101368525B1 (en) 2005-09-20 2014-03-06 노파르티스 아게 Use of a dpp-iv inhibitor to reduce hypoglycemic events
WO2007038979A1 (en) 2005-09-22 2007-04-12 Swissco Development Ag Effervescent metformin composition and tablets and granules made therefrom
JOP20180109A1 (en) 2005-09-29 2019-01-30 Novartis Ag New Formulation
JP2009510112A (en) 2005-09-30 2009-03-12 ノバルティス アクチエンゲゼルシャフト Combination of organic compounds
JP2009513633A (en) 2005-10-25 2009-04-02 メルク エンド カムパニー インコーポレーテッド Combination of dipeptidyl peptidase-4 inhibitor and antihypertensive agent for the treatment of diabetes and hypertension
WO2007052964A1 (en) 2005-11-04 2007-05-10 Ls Cable Ltd. Synthesis of mdh-polymer hybrid particles
AU2006333151B2 (en) 2005-12-16 2010-03-04 Merck Sharp & Dohme Llc Pharmaceutical compositions of combinations of dipeptidyl peptidase-4 inhibitors with metformin
WO2007071738A1 (en) 2005-12-23 2007-06-28 Novartis Ag Condensed heterocyclic compounds useful as dpp-iv inhibitors
GB0526291D0 (en) 2005-12-23 2006-02-01 Prosidion Ltd Therapeutic method
US20090054512A1 (en) 2006-01-06 2009-02-26 Foley James E Use of organic compounds
CA2635838A1 (en) 2006-02-15 2007-08-23 Boehringer Ingelheim International Gmbh Glucopyranosyl-substituted benzonitrile derivatives, pharmaceutical compositions containing such compounds, their use and process for their manufacture
WO2007099345A1 (en) 2006-03-02 2007-09-07 Betagenon Ab Medical use of bmp-2 and/ or bmp-4
PE20071221A1 (en) 2006-04-11 2007-12-14 Arena Pharm Inc GPR119 RECEPTOR AGONISTS IN METHODS TO INCREASE BONE MASS AND TO TREAT OSTEOPOROSIS AND OTHER CONDITIONS CHARACTERIZED BY LOW BONE MASS, AND COMBINED THERAPY RELATED TO THESE AGONISTS
US8455435B2 (en) 2006-04-19 2013-06-04 Ludwig-Maximilians-Universitat Munchen Remedies for ischemia
BRPI0711558A2 (en) 2006-05-04 2011-11-08 Boeringer Ingelheim Internat Gmbh polymorphs
PE20080251A1 (en) * 2006-05-04 2008-04-25 Boehringer Ingelheim Int USES OF DPP IV INHIBITORS
EP1852108A1 (en) 2006-05-04 2007-11-07 Boehringer Ingelheim Pharma GmbH & Co.KG DPP IV inhibitor formulations
KR20070111099A (en) 2006-05-16 2007-11-21 영진약품공업주식회사 Novel crystalline forms of cytagliptin hydrochloride, methods for their preparation and pharmaceutical compositions comprising the same
NZ572368A (en) 2006-05-16 2011-04-29 Gilead Sciences Inc Method and compositions for treating hematological malignancies
WO2007137107A2 (en) 2006-05-19 2007-11-29 Abbott Laboratories Inhibitors of diacylglycerol o-acyltransferase type 1 enzyme
KR100858848B1 (en) 2006-05-23 2008-09-17 한올제약주식회사 Metformin sustained-release tablet
WO2007149797A2 (en) 2006-06-19 2007-12-27 Novartis Ag Use of organic compounds
WO2007148185A2 (en) 2006-06-21 2007-12-27 Pfizer Products Inc. Substituted 3 -amino- pyrrolidino-4 -lactams as dpp inhibitors
AT503443B1 (en) 2006-06-23 2007-10-15 Leopold Franzens Uni Innsbruck Preparation of an ice surface, useful for ice rink, and ice sports cars and trains, comprises freezing water in which an inorganic substance e.g. ammonia, alkali hydroxide, hydrogen halide, nitric acid and sulfuric acid, is added
TW200811147A (en) 2006-07-06 2008-03-01 Arena Pharm Inc Modulators of metabolism and the treatment of disorders related thereto
TW200811140A (en) 2006-07-06 2008-03-01 Arena Pharm Inc Modulators of metabolism and the treatment of disorders related thereto
EP2057160A1 (en) 2006-08-08 2009-05-13 Boehringer Ingelheim International GmbH Pyrrolo [3, 2 -d]pyrimidines as dpp-iv inhibitors for the treatment of diabetes mellitus
US8039441B2 (en) 2006-08-15 2011-10-18 Boehringer Ingelheim International Gmbh Glucopyranosyl-substituted cyclopropylbenzene derivatives, pharmaceutical compositions containing such compounds, their use as SGLT inhibitors and process for their manufacture
WO2008022267A2 (en) 2006-08-17 2008-02-21 Wellstat Therapeutics Corporation Combination treatment for metabolic disorders
DE102006042586B4 (en) 2006-09-11 2014-01-16 Betanie B.V. International Trading Process for the microparticulate loading of high polymer carbohydrates with hydrophobic active fluids
BRPI0717829A2 (en) 2006-10-03 2014-07-29 Wyeth Corp LYOPHILIZATION METHODS AND APPARATUS
US7956201B2 (en) 2006-11-06 2011-06-07 Hoffman-La Roche Inc. Process for the preparation of (S)-4-fluoromethyl-dihydro-furan-2-one
AR063569A1 (en) 2006-11-06 2009-02-04 Boehringer Ingelheim Int DERIVATIVES OF BENZIL- BENZONITRILE SUBSTITUTED WITH GLUCOPYRANOSIL MEDICINES CONTAINING COMPOUNDS OF THIS TYPE ITS USE OR PROCEDURE FOR MANUFACTURING
CA3007700A1 (en) 2006-11-09 2008-05-15 Boehringer Ingelheim International Gmbh Combination therapy with sglt-2 inhibitors and their pharmaceutical compositions
EA015835B1 (en) 2006-12-06 2011-12-30 Смитклайн Бичем Корпорейшн 4-oxa(thia)methylpiperidine derivatives, use thereof as antidiabetic compounds
ES2319596B1 (en) 2006-12-22 2010-02-08 Laboratorios Almirall S.A. NEW DERIVATIVES OF THE AMINO-NICOTINIC AND AMINO-ISONICOTINIC ACIDS.
US7638541B2 (en) 2006-12-28 2009-12-29 Metabolex Inc. 5-ethyl-2-{4-[4-(4-tetrazol-1-yl-phenoxymethyl)-thiazol-2-yl]-piperidin-1-yl}-pyrimidine
AR064736A1 (en) 2007-01-04 2009-04-22 Prosidion Ltd GPCR AGONISTS
CL2008000133A1 (en) 2007-01-19 2008-05-23 Boehringer Ingelheim Int PHARMACEUTICAL COMPOSITION THAT INCLUDES A COMPOUND DERIVED FROM PIRAZOL-O-GLUCOSIDE COMBINED WITH AT LEAST A SECOND THERAPEUTIC AGENT; AND USE OF THE COMPOSITION FOR THE TREATMENT OF MELLITUS DIABETES, CATARATS, NEUROPATHY, MYOCARDIAL INFARTS, AND
WO2008093878A1 (en) 2007-02-01 2008-08-07 Takeda Pharmaceutical Company Limited Tablet preparation without causing a tableting trouble
PL2107905T3 (en) 2007-02-01 2011-04-29 Takeda Pharmaceuticals Co Solid preparation comprising alogliptin and pioglitazone
NZ579040A (en) 2007-02-06 2011-01-28 Chelsea Therapeutics Inc New compounds, methods for their preparation and use thereof
WO2008114800A2 (en) 2007-03-13 2008-09-25 Takeda Pharmaceutical Company Limited Solid preparation comprising 2- [ [6- [ (3r) -3-amino-1-piperidinyl] -3, 4-dihydro-3-methyl-2, 4-dioxo-1 (2h) -pyrimidinyl] methyl] -4-fluorobenzonitrile
CA2681092A1 (en) 2007-03-15 2008-09-18 Nectid, Inc. Anti-diabetic combinations comprising a slow release biguanide composition and an immediate release dipeptidyl peptidase iv inhibitor composition
CA2682736C (en) 2007-04-03 2013-07-09 Mitsubishi Tanabe Pharma Corporation Combined use of dipeptidyl peptidase 4 inhibitor and sweetener
US9050123B2 (en) 2007-04-16 2015-06-09 Smith & Nephew, Inc. Powered surgical system
PE20090696A1 (en) 2007-04-20 2009-06-20 Bristol Myers Squibb Co CRYSTALLINE FORMS OF SAXAGLIPTIN AND PROCESSES FOR PREPARING THEM
ES2388967T3 (en) 2007-05-04 2012-10-22 Bristol-Myers Squibb Company Agonists [6,6] - and [6,7] -cyclics of the GPR119 receptor coupled to the G protein
WO2007135196A2 (en) 2007-07-09 2007-11-29 Symrise Gmbh & Co. Kg Stable soluble salts of phenylbenzimidazole sulfonic acid at phs at or below 7.0
WO2009011451A1 (en) 2007-07-19 2009-01-22 Takeda Pharmaceutical Company Limited Solid preparation comprising alogliptin and metformin hydrochloride
CL2008002425A1 (en) 2007-08-16 2009-09-11 Boehringer Ingelheim Int Pharmaceutical composition comprising an inhibitor of sglt2 and 1- (4-methyl-quinazolin-2-yl) methyl-3-methyl-7 - (- 2-butin-1-yl) -8- (3- (r) -amino- Piperidin-1yl) -xanthine, an iv dpp inhibitor and its use for the treatment of obesity and type 1 and 2 diabetes and complications thereof.
PE20090987A1 (en) 2007-08-16 2009-08-14 Boehringer Ingelheim Int PHARMACEUTICAL COMPOSITION INCLUDING A DERIVATIVE OF PIRAZOL-O-GLUCOSIDE
CL2008002427A1 (en) 2007-08-16 2009-09-11 Boehringer Ingelheim Int Pharmaceutical composition comprising 1-chloro-4- (bd-glucopyranos-1-yl) -2- [4 - ((s) -tetrahydrofuran-3-yloxy) benzyl] -benzene combined with 1 - [(4-methylquinazolin- 2-yl) methyl] -3-methyl-7- (2-butyn-1-yl) -8- (3- (r) -aminopiperidin-1-yl) xanthine; and its use to treat type 2 diabetes mellitus.
PE20090597A1 (en) 2007-08-16 2009-06-06 Boehringer Ingelheim Int PHARMACEUTICAL COMPOSITION INCLUDING A DERIVATIVE OF PIRAZOL-O-GLUCOSIDE
KR101610005B1 (en) 2007-08-17 2016-04-08 베링거 인겔하임 인터내셔날 게엠베하 Purin derivatives for use in the treatment of FAB-related diseases
US8338450B2 (en) 2007-09-21 2012-12-25 Lupin Limited Compounds as dipeptidyl peptidase IV (DPP IV) inhibitors
MX2010005245A (en) 2007-11-16 2010-06-01 Novo Nordisk As Pharmaceutical compositions containing insulin and an insulinotropic peptide.
CN101234105A (en) 2008-01-09 2008-08-06 北京润德康医药技术有限公司 Pharmaceutical composition containing diabetosan and vildagliptin and preparation thereof
CL2008003653A1 (en) 2008-01-17 2010-03-05 Mitsubishi Tanabe Pharma Corp Use of a glucopyranosyl-derived sglt inhibitor and a selected dppiv inhibitor to treat diabetes; and pharmaceutical composition.
US20090186086A1 (en) 2008-01-17 2009-07-23 Par Pharmaceutical, Inc. Solid multilayer oral dosage forms
TW200936136A (en) 2008-01-28 2009-09-01 Sanofi Aventis Tetrahydroquinoxaline urea derivatives, their preparation and their therapeutic application
US20100330177A1 (en) 2008-02-05 2010-12-30 Merck Sharp & Dohme Corp. Pharmaceutical compositions of a combination of metformin and a dipeptidyl peptidase-iv inhibitor
CN101959406A (en) 2008-03-04 2011-01-26 默沙东公司 Pharmaceutical compositions of a combination of metformin and a dipeptidyl peptidase-IV inhibitor
US8436043B2 (en) 2008-03-05 2013-05-07 Takeda Pharmaceutical Company Limited Heterocyclic compound
US8551524B2 (en) 2008-03-14 2013-10-08 Iycus, Llc Anti-diabetic combinations
ES2543358T3 (en) 2008-03-31 2015-08-18 Cymabay Therapeutics, Inc. Oxymethylene aryl compounds and uses thereof
PE20140960A1 (en) 2008-04-03 2014-08-15 Boehringer Ingelheim Int FORMULATIONS INVOLVING A DPP4 INHIBITOR
CN101590007A (en) 2008-05-27 2009-12-02 北京瑞伊人科技发展有限公司 A kind of metformin hydrochloride/voigelibo sugar-lowering oral preparation compositions and preparation thereof
PE20100156A1 (en) 2008-06-03 2010-02-23 Boehringer Ingelheim Int NAFLD TREATMENT
UY32030A (en) 2008-08-06 2010-03-26 Boehringer Ingelheim Int "TREATMENT FOR DIABETES IN INAPPROPRIATE PATIENTS FOR THERAPY WITH METFORMIN"
KR20190016601A (en) 2008-08-06 2019-02-18 베링거 인겔하임 인터내셔날 게엠베하 Treatment for diabetes in patients inappropriate for metformin therapy
AU2009281122C1 (en) 2008-08-15 2016-04-21 Boehringer Ingelheim International Gmbh Purin derivatives for use in the treatment of fab-related diseases
JP2010053576A (en) 2008-08-27 2010-03-11 Sumitomo Forestry Co Ltd Mat for paving
EP2344195A2 (en) 2008-09-10 2011-07-20 Boehringer Ingelheim International GmbH Combination therapy for the treatment of diabetes and related conditions
UY32177A (en) 2008-10-16 2010-05-31 Boehringer Ingelheim Int TREATMENT OF DIABETES IN PATIENTS WITH INSUFFICIENT GLUCEMIC CONTROL TO WEIGHT THERAPY WITH DRUG, ORAL OR NOT, ANTIDIABÉTICO
WO2010045656A2 (en) 2008-10-17 2010-04-22 Nectid, Inc. Novel sglt2 inhibitor dosage forms
NZ592924A (en) 2008-12-23 2014-05-30 Boehringer Ingelheim Int Salt forms of a xanthine derivative
AR074990A1 (en) 2009-01-07 2011-03-02 Boehringer Ingelheim Int TREATMENT OF DIABETES IN PATIENTS WITH AN INAPPROPRIATE GLUCEMIC CONTROL THROUGH METFORMIN THERAPY
TWI466672B (en) 2009-01-29 2015-01-01 Boehringer Ingelheim Int Treatment for diabetes in paediatric patients
CN104906582A (en) 2009-02-13 2015-09-16 勃林格殷格翰国际有限公司 Pharmaceutical composition comprising a SGLT2 inhibitor, a DPP-IV inhibitor and optionally a further antidiabetic agent and uses thereof
UY32427A (en) 2009-02-13 2010-09-30 Boheringer Ingelheim Internat Gmbh PHARMACEUTICAL COMPOSITION, PHARMACEUTICAL FORM, PROCEDURE FOR PREPARATION, METHODS OF TREATMENT AND USES OF THE SAME
MX2011008416A (en) 2009-02-13 2011-09-08 Boehringer Ingelheim Int Antidiabetic medications comprising a dpp-4 inhibitor (linagliptin) optionally in combination with other antidiabetics.
TW201031661A (en) 2009-02-17 2010-09-01 Targacept Inc Fused benzazepines as neuronal nicotinic acetylcholine receptor ligands
WO2010106457A2 (en) 2009-03-20 2010-09-23 Pfizer Inc. 3-oxa-7-azabicyclo[3.3.1]nonanes
US8815292B2 (en) 2009-04-27 2014-08-26 Revalesio Corporation Compositions and methods for treating insulin resistance and diabetes mellitus
MX2011011333A (en) 2009-04-27 2011-11-18 Revalesio Corp Compositions and methods for treating insulin resistance and diabetes mellitus.
US20120100221A1 (en) 2009-06-02 2012-04-26 Ranbaxy Laboratories Limited Pharmaceutical compositions containing a combination of an antihistamine and a decongestant
US20120059011A1 (en) 2009-06-15 2012-03-08 Nicholas Birringer Pharmaceutical compositions of combinations of dipeptidyl peptidase-4 inhibitors with pioglitazone
MX2012000892A (en) 2009-07-21 2012-06-01 Keryx Biopharmaceuticals Inc Ferric citrate dosage forms.
BR112012007234A2 (en) 2009-10-02 2016-04-05 Boehringer Ingelheim Int pharmaceutical combination comprising dpp-4 inhibitor and metformin, as well as their use and preparation process
UY32919A (en) 2009-10-02 2011-04-29 Boehringer Ingelheim Int Pharmaceutical composition, pharmaceutical dosage form, procedure for its preparation, methods for its treatment and its uses
JP5446716B2 (en) 2009-10-21 2014-03-19 大正製薬株式会社 Method for producing tablets containing arginine and carnitine
KR20240090632A (en) 2009-11-27 2024-06-21 베링거 인겔하임 인터내셔날 게엠베하 Treatment of genotyped diabetic patients with dpp-iv inhibitors such as linagliptin
JP2010070576A (en) 2009-12-28 2010-04-02 Sato Pharmaceutical Co Ltd Rapidly soluble tablet
TWI562775B (en) 2010-03-02 2016-12-21 Lexicon Pharmaceuticals Inc Methods of using inhibitors of sodium-glucose cotransporters 1 and 2
WO2011113947A1 (en) 2010-03-18 2011-09-22 Boehringer Ingelheim International Gmbh Combination of a gpr119 agonist and the dpp-iv inhibitor linagliptin for use in the treatment of diabetes and related conditions
US9186392B2 (en) 2010-05-05 2015-11-17 Boehringer Ingelheim International Gmbh Combination therapy
KR20130069615A (en) 2010-05-05 2013-06-26 베링거 인겔하임 인터내셔날 게엠베하 Pharmaceutical formulations comprising pioglitazone and linagliptin
JP5707489B2 (en) 2010-06-09 2015-04-30 ポクセル・エスアーエスＰｏｘｅｌｓａｓ Treatment of type 1 diabetes
CA2802335A1 (en) 2010-06-22 2011-12-29 Twi Pharmaceuticals, Inc. Controlled release compositions with reduced food effect
EP3725325B1 (en) 2010-06-24 2023-05-31 Boehringer Ingelheim International GmbH Diabetes therapy
CN103370064A (en) 2010-09-03 2013-10-23 百时美施贵宝公司 Pharmaceutical formulations using water-soluble antioxidants
WO2012039420A1 (en) 2010-09-21 2012-03-29 国立大学法人九州大学 Bionic aortic baroreflex system for treating disease associated with aortic baroreflex dysfunction
US9034883B2 (en) 2010-11-15 2015-05-19 Boehringer Ingelheim International Gmbh Vasoprotective and cardioprotective antidiabetic therapy
WO2012088682A1 (en) 2010-12-29 2012-07-05 Shanghai Fochon Pharmaceutical Co Ltd. 2-(3-aminopiperidin-1-yl)-[1,2,4]triazolo[1,5-c]pyrimidine-5,7(3h,6h)-dione derivates as dipeptidyl peptidase iv(dpp-iv) inhibitors
JP2014504639A (en) 2011-02-01 2014-02-24 ブリストル−マイヤーズ スクイブ カンパニー Pharmaceutical formulations containing amine compounds
AR085689A1 (en) 2011-03-07 2013-10-23 Boehringer Ingelheim Int PHARMACEUTICAL COMPOSITIONS OF METFORMIN, LINAGLIPTINE AND AN SGLT-2 INHIBITOR
US8785455B2 (en) 2011-05-10 2014-07-22 Sandoz Ag Polymorph of linagliptin benzoate
CN103781788B (en) 2011-07-15 2016-08-17 勃林格殷格翰国际有限公司 Quinazoline, its preparation and the purposes in pharmaceutical composition thereof being substituted
US20130172244A1 (en) 2011-12-29 2013-07-04 Thomas Klein Subcutaneous therapeutic use of dpp-4 inhibitor
BR112014016633B1 (en) 2012-01-04 2021-12-21 The Procter & Gamble Company FIBROUS STRUCTURES WITH MULTIPLE REGIONS CONTAINING ACTIVE AGENT AND METHOD TO TREAT A TISSUE ARTICLE IN NEED OF TREATMENT
US9555001B2 (en) 2012-03-07 2017-01-31 Boehringer Ingelheim International Gmbh Pharmaceutical composition and uses thereof
ES2929025T3 (en) 2012-05-14 2022-11-24 Boehringer Ingelheim Int Linagliptin, a xanthine derivative as a dpp-4 inhibitor, for use in the treatment of SIRS and/or sepsis
EP2849755A1 (en) 2012-05-14 2015-03-25 Boehringer Ingelheim International GmbH A xanthine derivative as dpp -4 inhibitor for use in the treatment of podocytes related disorders and/or nephrotic syndrome
WO2013174768A1 (en) 2012-05-24 2013-11-28 Boehringer Ingelheim International Gmbh A xanthine derivative as dpp -4 inhibitor for use in the treatment of autoimmune diabetes, particularly lada
WO2013174767A1 (en) 2012-05-24 2013-11-28 Boehringer Ingelheim International Gmbh A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference
JP2015518843A (en) 2012-05-25 2015-07-06 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Use of keratinocytes as bioactive agents that may be combined with DPP-4 inhibitors in the treatment of wounds, for example diabetic wounds
WO2013179307A2 (en) 2012-05-29 2013-12-05 Mylan Laboratories Limited Stabilized pharmaceutical compositions of saxagliptin
PT2887961T (en) 2012-08-24 2021-07-28 Novartis Ag Nep inhibitors for treating diseases characterized by atrial enlargement or remodeling
WO2014056942A1 (en) 2012-10-09 2014-04-17 Boehringer Ingelheim International Gmbh Use of selectively moisture-adjusted tabletting material in the production of mechanically stable tablets which contain at least one hydrate-forming active substance and/or adjuvant relevant to the mechanical stability of the tablets, particularly arginine-containing tablets
JP2015533133A (en) 2012-10-09 2015-11-19 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Use of moisture-control disintegrants in tablet manufacture
US9050302B2 (en) 2013-03-01 2015-06-09 Jazz Pharmaceuticals Ireland Limited Method of administration of gamma hydroxybutyrate with monocarboxylate transporters
WO2014140284A1 (en) 2013-03-15 2014-09-18 Boehringer Ingelheim International Gmbh Use of linagliptin in cardio- and renoprotective antidiabetic therapy
HK1215378A1 (en) 2013-04-18 2016-08-26 勃林格殷格翰国际有限公司 Pharmaceutical composition, methods for treating and uses thereof
US20140343014A1 (en) 2013-05-17 2014-11-20 Boehringer Ingelheim International Gmbh Combination of a certain dpp-4 inhibitor and voglibose
KR102238860B1 (en) 2013-06-14 2021-04-12 베링거 인겔하임 인터내셔날 게엠베하 Dpp-4 inhibitors for treating diabetes and its complications
CN104418857A (en) 2013-08-22 2015-03-18 北京蓝丹医药科技有限公司 Amorphous linagliptin and preparation method thereof
JP6615109B2 (en) 2014-02-28 2019-12-04 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Medical use of DPP-4 inhibitors
CN104130258B (en) 2014-08-13 2016-06-01 广东东阳光药业有限公司 The method for transformation of a kind of dimer
US20160106677A1 (en) 2014-10-17 2016-04-21 Boehringer Ingelheim International Gmbh Pharmaceutical composition and uses thereof
WO2016089373A1 (en) 2014-12-02 2016-06-09 Halliburton Energy Services, Inc. Integrated heat-exchanging mold systems
KR102442536B1 (en) 2015-09-17 2022-09-13 한미정밀화학주식회사 Linagliptin crystalline form and preparation method thereof
CN105272982B (en) 2015-11-23 2017-06-16 齐鲁制药有限公司 Li Gelieting novel crystal forms and preparation method thereof
KR102391564B1 (en) 2016-06-10 2022-04-29 베링거 인겔하임 인터내셔날 게엠베하 Combination of Linagliptin and Metformin
US20210299129A1 (en) 2018-07-17 2021-09-30 Boehringer Ingelheim International Gmbh Cardiosafe Antidiabetic Therapy
US11752145B2 (en) 2020-03-30 2023-09-12 Sanjay Gupta Quinoline derivatives with other anti-viral agents

Cited By (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10023574B2 (en) 2002-08-21 2018-07-17 Boehringer Ingelheim International Gmbh 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
US9556175B2 (en) 2002-08-21 2017-01-31 Boehringer Ingelheim International Gmbh 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and thier use as pharmaceutical compositions
US9321791B2 (en) 2002-08-21 2016-04-26 Boehringer Ingelheim International Gmbh 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
US8664232B2 (en) 2002-08-21 2014-03-04 Boehringer Ingelheim Pharma Gmbh & Co. Kg 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
US9108964B2 (en) 2002-08-21 2015-08-18 Boehringer Ingelheim International Gmbh 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
US8178541B2 (en) 2002-08-21 2012-05-15 Boehringer Ingelheim Pharma Gmbh & Co. Kg 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
US10202383B2 (en) 2002-08-21 2019-02-12 Boehringer Ingelheim International Gmbh 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
US8697868B2 (en) 2004-02-18 2014-04-15 Boehringer Ingelheim International Gmbh 8-[3-amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical compositions
US9499546B2 (en) 2004-11-05 2016-11-22 Boehringer Ingelheim International Gmbh Process for the preparation of chiral 8-(3-aminopiperidin-1-yl)-xanthines
US8541450B2 (en) 2004-11-05 2013-09-24 Boehringer Ingelheim International Gmbh Process for the preparation of chiral 8-(3-aminopiperidin-1yl)-xanthines
US9751855B2 (en) 2004-11-05 2017-09-05 Boehringer Ingelheim International Gmbh Process for the preparation of chiral 8-(3-aminopiperidin-1-yl)-xanthines
US8883805B2 (en) 2004-11-05 2014-11-11 Boehringer Ingelheim International Gmbh Process for the preparation of chiral 8-(3-aminopiperidin-1-yl)-xanthines
US8637530B2 (en) 2005-07-30 2014-01-28 Boehringer Ingelheim International Gmbh 8-(3-amino-piperidin-1-yl)-xanthines, their preparation, and their use as pharmaceuticals
US10080754B2 (en) 2006-05-04 2018-09-25 Boehringer Ingelheim International Gmbh Uses of DPP IV inhibitors
US9815837B2 (en) 2006-05-04 2017-11-14 Boehringer Ingelheim International Gmbh Polymorphs
US12171767B2 (en) 2006-05-04 2024-12-24 Boehringer Ingelheim International Gmbh Uses of DPP IV inhibitors
US11033552B2 (en) 2006-05-04 2021-06-15 Boehringer Ingelheim International Gmbh DPP IV inhibitor formulations
US11084819B2 (en) 2006-05-04 2021-08-10 Boehringer Ingelheim International Gmbh Polymorphs
US12178819B2 (en) 2006-05-04 2024-12-31 Boehringer Ingelheim International Gmbh DPP IV inhibitor formulations
US8232281B2 (en) 2006-05-04 2012-07-31 Boehringer Ingelheim International Gmbh Uses of DPP-IV inhibitors
US9173859B2 (en) 2006-05-04 2015-11-03 Boehringer Ingelheim International Gmbh Uses of DPP IV inhibitors
US9493462B2 (en) 2006-05-04 2016-11-15 Boehringer Ingelheim International Gmbh Polymorphs
US10301313B2 (en) 2006-05-04 2019-05-28 Boehringer Ingelheim International Gmbh Polymorphs
US8673927B2 (en) 2006-05-04 2014-03-18 Boehringer Ingelheim International Gmbh Uses of DPP-IV inhibitors
US9266888B2 (en) 2006-05-04 2016-02-23 Boehringer Ingelheim International Gmbh Polymorphs
US11291668B2 (en) 2006-05-04 2022-04-05 Boehringer Ingelheim International Gmbh Uses of DPP IV inhibitors
US11919903B2 (en) 2006-05-04 2024-03-05 Boehringer Ingelheim International Gmbh Polymorphs
US8551957B2 (en) 2007-08-16 2013-10-08 Boehringer Ingelheim International Gmbh Pharmaceutical composition comprising a glucopyranosyl-substituted benzene derivate
US9415016B2 (en) 2008-04-03 2016-08-16 Boehringer Ingelheim International Gmbh DPP-IV inhibitor combined with a further antidiabetic agent, tablets comprising such formulations, their use and process for their preparation
US10022379B2 (en) 2008-04-03 2018-07-17 Boehringer Ingelheim International Gmbh DPP-IV inhibitor combined with a further antidiabetic agent, tablets comprising such formulations, their use and process for their preparation
US9155705B2 (en) 2008-04-03 2015-10-13 Boehringer Ingelheim International Gmbh DPP-IV inhibitor combined with a further antidiabetic agent, tablets comprising such formulations, their use and process for their preparation
US10973827B2 (en) 2008-04-03 2021-04-13 Boehringer Ingelheim International Gmbh DPP-IV inhibitor combined with a further antidiabetic agent, tablets comprising such formulations, their use and process for their preparation
US9486526B2 (en) 2008-08-06 2016-11-08 Boehringer Ingelheim International Gmbh Treatment for diabetes in patients inappropriate for metformin therapy
US8853156B2 (en) 2008-08-06 2014-10-07 Boehringer Ingelheim International Gmbh Treatment for diabetes in patients inappropriate for metformin therapy
US10034877B2 (en) 2008-08-06 2018-07-31 Boehringer Ingelheim International Gmbh Treatment for diabetes in patients inappropriate for metformin therapy
US8513264B2 (en) 2008-09-10 2013-08-20 Boehringer Ingelheim International Gmbh Combination therapy for the treatment of diabetes and related conditions
US11911388B2 (en) 2008-10-16 2024-02-27 Boehringer Ingelheim International Gmbh Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral or non-oral antidiabetic drug
US8865729B2 (en) 2008-12-23 2014-10-21 Boehringer Ingelheim International Gmbh Salt forms of a xanthine compound
US9212183B2 (en) 2008-12-23 2015-12-15 Boehringer Ingelheim International Gmbh Salt forms of 1-[(4-methyl-quinazolin-2-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-(3-(R)-amino-piperidin-1-yl)-xanthine
US8846695B2 (en) 2009-01-07 2014-09-30 Boehringer Ingelheim International Gmbh Treatment for diabetes in patients with inadequate glycemic control despite metformin therapy comprising a DPP-IV inhibitor
US12115179B2 (en) 2009-02-13 2024-10-15 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
US10406172B2 (en) 2009-02-13 2019-09-10 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
US9457029B2 (en) 2009-11-27 2016-10-04 Boehringer Ingelheim International Gmbh Treatment of genotyped diabetic patients with DPP-IV inhibitors such as linagliptin
US10092571B2 (en) 2009-11-27 2018-10-09 Boehringer Ingelheim International Gmbh Treatment of genotyped diabetic patients with DPP-IV inhibitors such as linagliptin
US10004747B2 (en) 2010-05-05 2018-06-26 Boehringer Ingelheim International Gmbh Combination therapy
US9186392B2 (en) 2010-05-05 2015-11-17 Boehringer Ingelheim International Gmbh Combination therapy
US9603851B2 (en) 2010-05-05 2017-03-28 Boehringer Ingelheim International Gmbh Combination therapy
US9149478B2 (en) 2010-06-24 2015-10-06 Boehringer Ingelheim International Gmbh Diabetes therapy
US9034883B2 (en) 2010-11-15 2015-05-19 Boehringer Ingelheim International Gmbh Vasoprotective and cardioprotective antidiabetic therapy
US11911387B2 (en) 2010-11-15 2024-02-27 Boehringer Ingelheim International Gmbh Vasoprotective and cardioprotective antidiabetic therapy
US10596120B2 (en) 2011-03-07 2020-03-24 Boehringer Ingelheim International Gmbh Pharmaceutical compositions
US11564886B2 (en) 2011-03-07 2023-01-31 Boehringer Ingelheim International Gmbh Pharmaceutical compositions
US20180185291A1 (en) 2011-03-07 2018-07-05 Boehringer Ingelheim International Gmbh Pharmaceutical compositions
US8962636B2 (en) 2011-07-15 2015-02-24 Boehringer Ingelheim International Gmbh Substituted quinazolines, the preparation thereof and the use thereof in pharmaceutical compositions
US8883800B2 (en) 2011-07-15 2014-11-11 Boehringer Ingelheim International Gmbh Substituted quinazolines, the preparation thereof and the use thereof in pharmaceutical compositions
US9199998B2 (en) 2011-07-15 2015-12-01 Boehringer Ingelheim Internatioal Gmbh Substituted quinazolines, the preparation thereof and the use thereof in pharmaceutical compositions
US9555001B2 (en) 2012-03-07 2017-01-31 Boehringer Ingelheim International Gmbh Pharmaceutical composition and uses thereof
US9526730B2 (en) 2012-05-14 2016-12-27 Boehringer Ingelheim International Gmbh Use of a DPP-4 inhibitor in podocytes related disorders and/or nephrotic syndrome
US10195203B2 (en) 2012-05-14 2019-02-05 Boehringr Ingelheim International GmbH Use of a DPP-4 inhibitor in podocytes related disorders and/or nephrotic syndrome
US12312352B2 (en) 2012-05-14 2025-05-27 Boehringer Ingelheim International Gmbh Use of a DPP-4 inhibitor in SIRS and/or sepsis
US9713618B2 (en) 2012-05-24 2017-07-25 Boehringer Ingelheim International Gmbh Method for modifying food intake and regulating food preference with a DPP-4 inhibitor
WO2014080384A1 (en) 2012-11-26 2014-05-30 Ranbaxy Laboratories Limited Pharmaceutical composition of linagliptin
US9526728B2 (en) 2014-02-28 2016-12-27 Boehringer Ingelheim International Gmbh Medical use of a DPP-4 inhibitor
EP3156048A1 (en) 2015-10-13 2017-04-19 Galenicum Health S.L. Stable pharmaceutical composition of linagliptin in the form of immediate release tablets
US10155000B2 (en) 2016-06-10 2018-12-18 Boehringer Ingelheim International Gmbh Medical use of pharmaceutical combination or composition
US12364700B2 (en) 2016-06-10 2025-07-22 Boehringer Ingelheim International Gmbh Medical use of pharmaceutical combination or composition

Also Published As

Publication number Publication date
UA94942C2 (en) 2011-06-25
JP2016104811A (en) 2016-06-09
TWI474843B (en) 2015-03-01
NO20084256L (en) 2008-12-02
CL2012002521A1 (en) 2012-12-21
KR102051281B1 (en) 2019-12-03
IL195030A (en) 2013-09-30
ME01941B (en) 2015-05-20
NZ595983A (en) 2013-08-30
CN101437493A (en) 2009-05-20
TW201417844A (en) 2014-05-16
EA016559B1 (en) 2012-05-30
SG171649A1 (en) 2011-06-29
NZ572862A (en) 2011-11-25
JP2018021082A (en) 2018-02-08
EA029890B1 (en) 2018-05-31
JP7084711B2 (en) 2022-06-15
JP5478244B2 (en) 2014-04-23
JP6100998B2 (en) 2017-03-22
SI2023902T1 (en) 2011-01-31
PL2283819T3 (en) 2015-03-31
AR079930A2 (en) 2012-02-29
ES2527409T3 (en) 2015-01-23
US12178819B2 (en) 2024-12-31
EP2023902B1 (en) 2010-09-08
BRPI0711179B1 (en) 2022-02-08
EP2283819B1 (en) 2014-10-08
PL2277509T3 (en) 2015-07-31
RS51466B (en) 2011-04-30
MX384206B (en) 2025-03-14
HRP20100507T1 (en) 2010-10-31
CY1116064T1 (en) 2017-02-08
MY148496A (en) 2013-04-30
EP1852108A1 (en) 2007-11-07
AU2007247193A1 (en) 2007-11-15
KR101710881B1 (en) 2017-02-28
ECSP088800A (en) 2008-11-27
EA201100958A1 (en) 2012-04-30
JP2024074800A (en) 2024-05-31
BRPI0711179A2 (en) 2011-05-03
SI2283819T1 (en) 2015-01-30
KR20090009226A (en) 2009-01-22
HK1172549A1 (en) 2013-04-26
MY146969A (en) 2012-10-15
ES2527409T4 (en) 2015-03-11
JP2012072187A (en) 2012-04-12
HRP20150003T1 (en) 2015-03-13
HUE025210T2 (en) 2016-03-29
CN102526737B (en) 2015-02-25
WO2007128724A1 (en) 2007-11-15
EP2910241A1 (en) 2015-08-26
US20210260068A1 (en) 2021-08-26
CA2649922A1 (en) 2007-11-15
PE20080698A1 (en) 2008-08-04
NZ613426A (en) 2015-02-27
BRPI0722388B1 (en) 2022-09-27
CA2649922C (en) 2014-02-04
PL2023902T4 (en) 2011-06-30
BRPI0722388A2 (en) 2015-05-19
IL212841A0 (en) 2011-07-31
DK2023902T3 (en) 2010-11-15
EP2277509B1 (en) 2015-03-11
EP2023902B8 (en) 2010-11-24
DK2277509T5 (en) 2015-06-08
US20120219622A1 (en) 2012-08-30
DK2277509T3 (en) 2015-04-13
ME01170B (en) 2013-03-20
JP6564720B2 (en) 2019-08-21
HRP20150003T2 (en) 2015-12-18
JP2013227338A (en) 2013-11-07
US20250064818A1 (en) 2025-02-27
ZA200808361B (en) 2010-10-27
MX358617B (en) 2018-08-29
CN101437493B (en) 2013-10-23
US20080107731A1 (en) 2008-05-08
PL2023902T3 (en) 2011-03-31
US20170312287A1 (en) 2017-11-02
US20160022687A1 (en) 2016-01-28
US20130122089A1 (en) 2013-05-16
TW200812648A (en) 2008-03-16
IL195030A0 (en) 2009-08-03
TWI520753B (en) 2016-02-11
RS53570B1 (en) 2015-02-27
ES2538818T3 (en) 2015-06-24
KR101855323B1 (en) 2018-05-09
PE20110666A1 (en) 2011-09-23
KR20170141812A (en) 2017-12-26
MX2008013958A (en) 2008-11-12
HK1130442A1 (en) 2009-12-31
JP2009535376A (en) 2009-10-01
KR20150100957A (en) 2015-09-02
PT2283819E (en) 2014-11-03
EP2283819A1 (en) 2011-02-16
KR20160128446A (en) 2016-11-07
DE602007009091D1 (en) 2010-10-21
EP2277509A1 (en) 2011-01-26
NO343067B1 (en) 2018-10-22
EA200802184A1 (en) 2009-06-30
KR20140063896A (en) 2014-05-27
ATE480228T1 (en) 2010-09-15
US11033552B2 (en) 2021-06-15
PT2023902E (en) 2010-10-12
CN102526737A (en) 2012-07-04
JP2020079316A (en) 2020-05-28
JP2022075826A (en) 2022-05-18
CY1111354T1 (en) 2015-08-05
US20190209571A1 (en) 2019-07-11
EP2283819B9 (en) 2015-03-11
AU2007247193B2 (en) 2013-05-16
CL2012002522A1 (en) 2012-12-21
KR101478983B1 (en) 2015-01-05
EP2023902A1 (en) 2009-02-18
ES2348576T3 (en) 2010-12-09
UY30319A1 (en) 2008-01-02
JP6987908B2 (en) 2022-01-05
KR102051281B9 (en) 2024-08-12
DK2283819T3 (en) 2015-01-05
AR060755A1 (en) 2008-07-10

Similar Documents

Publication Publication Date Title
US12178819B2 (en) DPP IV inhibitor formulations
JP2009535376A6 (en) DPP IV inhibitor formulation
JP2013227338A6 (en) DPP IV inhibitor formulation
HK1172549B (en) Dpp iv inhibitor formulations
HK1130442B (en) Dpp iv inhibitor formulations

Legal Events

Date Code Title Description
STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION